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Paper I 















Smoking is one of the most important causes of cancer and premature death worldwide. Two 
different reports, the most recent monograph published by International Agency for Research 
on Cancer (IARC) in 2012 and the Unites States Surgeon General’s report of 2014, concluded 
that smoking is risk factor for both colon and rectal cancer. In addition to being one of the 
most common cancers in Norway, mortality from colorectal cancer (CRC) is also high. The 
main aim of this thesis was to examine the association between smoking and CRC incidence 
and mortality overall and by gender. We examined the association between smoking and 
colon cancer by location and gender (Paper I), rectal cancer by gender (Paper II) and CRC 
mortality by subsite and gender (Paper III). 
The cohort included 652,792 Norwegians (49% men) recruited from four Norwegian health 
screening surveys. These surveys were conducted between 1972 and 2003: the Oslo study I 
(1972-1973), the Norwegian counties study (1974-1988), the 40 years cohort (1985-1999) and 
the Cohort of Norway (CONOR, 1994-2003). The participation rate for the different surveys 
varied from 56-88%. 
Women ever smokers had a 19% and men ever smokers had 8% increased risk of colon 
cancer. Furthermore, women ever smokers had an increased risk of proximal colon cancer 
compared to men ever smokers (Paper I). Ever smokers had an increased risk of rectal cancer 
at around 25% and the risk increased was similar for men and women (Paper II). Men and 
women ever smokers had a similar increased risk of CRC mortality of about 20%. The risk of 
rectal and proximal colon cancer mortality was most pronounced among men and women 
smokers, respectively (Paper III). 
In conclusion, smoking increased the risk of colon cancer, especially proximal colon cancer 
among women. Furthermore, smoking increased the risk of rectal cancer, with a similar risk 
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being observed among women as in men ever smokers. Smoking is associated with increased 
CRC mortality among both men and women. The risk of rectal and proximal cancer mortality 
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This thesis describes the association between cigarette smoking and colorectal cancer (CRC) 
incidence and mortality overall and by subsite among Norwegian men and women who 
participated in four different Norwegian health surveys. 
1.1 Definition and epidemiology of colorectal cancer  
In 2012, there were around 14 million new cancer cases (all types combined), 8 million cancer 
deaths and around 32 million people were living with cancer worldwide. Fifty-seven percent 
(8 million) of these new cancer cases and 65% (5.3 million) of cancer deaths occurred in low 
and medium income countries (1). 
CRC is one of the major causes of morbidity and mortality around the world (2). CRC is 
confined to the main parts of large intestine, the colon and rectum. Adenocarcinoma is the 
predominant histological subtype and begins as adenomatous polyps before reaching the 
malignant stage. The progression from adenomatous polyps to carcinoma occurs with 
potential damage to DNA. Other histological subtypes of CRC include carcinoid tumors, 
gastrointestinal, stromal tumors, lymphomas and sarcomas. More than 95% CRC are sporadic, 
originating in individual without significant genetic or hereditary risk factor (3). If the 
diagnosis is made early, CRC is highly treatable. CRC is known as disease of western world 
as it is more prevalent in high-income countries. 
Globally, CRC is the third most common cancer in men and the second most common cancer 
in women representing about 9% and 10% of all incident cancer respectively (2). CRC 
incidence rates worldwide have changed with time, but usually men have higher rates 
compared to women (2). There is a wide variation in CRC incidence across the world 
population but the patterns of variation in men and women are similar. The CRC incidence 
rates vary tenfold, with the highest estimates in Australia and New Zealand (age-standardized 
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incidence rate, ASR 44.8 and 32.2 per 100,000 in men and women, respectively) and the 
lowest in Western Africa (4.5 and 3.8 per 100,000 in men and women, respectively) (1). 
There is also a geographical difference in the global occurrence of CRC. High-income 
countries usually have higher incidence rates and accounts for almost 55% of all incident 
cases CRC worldwide (4). 
CRC incidence rates are decreasing in the United States, whereas in Northern and Western 
Europe CRC incidence rates are stabilizing. However, high income countries like Japan, 
Singapore, and some Eastern European countries are showing a substantial increase in CRC 
incidence (5;6). 
CRC accounts for 8% of all cancers deaths, which makes it the fourth most common cause of 
death from cancer worldwide (7). It has been reported that about 12% of CRC deaths are 
attributed to smoking (6;8). CRC mortality rates are lower in women than men except in the 
Caribbean region (7). Worldwide, CRC mortality rates vary less than CRC incidence rates 
(six fold in men, and four fold in women). The highest mortality rates are observed in Central 
and Eastern Europe (20.3 and 11.7 per 100.000 among men and women, respectively) and 
lowest in western Africa (3.5 and 3.0 per 100,000 among men and women, respectively) (1). 
In the United States, it is the third most common cause of cancer death although the overall 
mortality rates have decreased by 2.8% and 2.6% per year in men and women, respectively 
since 1998 (9). CRC is the second most common cause of cancer deaths in Europe (1). Latest 




Figure 1: Worldwide estimated age standardized rates of CRC incidence and mortality rates per 








1.2 Incidence of colorectal cancer in Nordic countries 
 
 
Figure 2: Estimated age standardized CRC incidence and mortality rates per 100,000 in Northern 
Europe by gender (Globocan 2012, IARC) 
 
 
Figure 2 illustrates the present CRC incidence and mortality rates in Northern Europe among 









Figure 3: Age standardized rate of CRC incidence and mortality rates per 100,000 in the Nordic 
countries 1972 and 2007 (NORDCAN) 
 
Figure 3 shows the incidence and mortality rates in the Nordic countries during 1972 and 
2007 that is the beginning and end of our study period, respectively. Denmark had the highest 
incidence rate back in 1972 both among men and women. By 2007, Norway and Denmark 
were observing almost similar CRC incidence rates. Norwegian women had slightly higher 
incidence rate compared to Danish women. However, regarding mortality rates, Icelandic men 
had the highest rates followed by Danish men during 1972 whereas by 2007 highest rates 
were observed in Denmark and Norway. Danish men had highest CRC mortality rate whereas 
the rates were highest among Norwegian women in 2007. 
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1.2 Colorectal cancer in Norway 
Over the last half century, Norway has experienced one of the most rapid and steady rises in 
CRC incidence. In the late 1950s, the age standardized incidence rate for colon cancer was 10 
per 100,000 for both men and women. The incidence rate of rectal cancer in the same period 
was approximately around 7 and 4 for per 100,000 for men and women, respectively. By the 
beginning of 1970s, the incidence rate of colon cancer was around 14 for both men and 
women; the incidence rate of rectal cancer was 11 and 8 per 100,000 for men and women, 
respectively. Current incidence rates of both colon and rectal cancer are more than double 
what they were 50 years ago for both men and women. The present age standardized five year 
incidence rate of CRC for year 2007-2011 is 43 for and 35 per 100,000 for men and women 
respectively. Among men, the incidence rate of colon and rectal cancer is 26 and 17 per 
100,000 respectively. Similarly, for women, the incidence of colon and rectal cancer is 24 and 
11 per 100,000 respectively (10). The corresponding figures for CRC incidence rate and by 
subsite in Norway by gender from 1972-2011 are presented in the figure below (Figure 4, 5, 
and 6). 
 
Figure 4: Age standardized incidence rate of colon cancer by gender in Norway (1972-2011) 















Figure 5: Age standardized incidence rate of rectal cancer by gender in Norway (1972-2011) 





Figure 6: Age standardized incidence rate of CRC by gender in Norway (1972-2011) 
(Source: Norwegian Cancer Registry, 2013) 
 
The colon cancer incidence rates among men and women are almost similar but men have 
higher incidence of rectal cancer than women. The gender difference in CRC incidence is due 





























Figure 7: Estimates of age standardized incidence and mortality rate per 100,000 for different cancer 
sites in Norway by gender (Globocan 2012) 
 
Figure 7 shows the ASR for different cancer in Norwegian by gender in 2012. In 2002, 
women in Norway had the highest CRC incidence rate in Europe and second highest 
incidence rate worldwide, only surpassed by women in New Zealand (11). In addition to 
being one of the most common cancers among Norwegian, CRC is also a cancer type with a 
high mortality. The latest report showed that in Norway, the CRC mortality rate is ranked 
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second after lung cancer among women and third after lung and prostate cancer among men 
(10). 
 
1.3 Prevalence of smoking 
1.3.1 Global prevalence  
There are an estimated 1.3 billion smokers worldwide and that number is expected to increase 
to 1.6 billion by 2025 (12;13). Seventy-three percent of smokers are from low and medium 
income countries. Smoking is one of the major leading preventable causes of death in the 
world (13-15) and attributed to approximately 6 million premature deaths each year globally. 
If prevention measures are not implemented soon, the deaths toll could reach approximately 8 
million by 2030. Recent report on tobacco from World Health Organization (WHO) reported 
that in the 20th century almost 100 million deaths have been caused by tobacco smoking and 
if this trend continues further, one billion smoking related deaths will occur in the 21st 
century (13). 
A four stage model for describing the effects of smoking on mortality was purposed by Lopez 
and colleagues almost 2 decades ago (16). Women in high-income countries lagged behind 
men by 20-30 years in relation to smoking and its attributed mortality. This model was further 
reviewed in 2012 and the predictions matched recent trends in smoking and smoking related 
mortality (Figure 8). The authors concluded that the model reflected the situation of many 





Figure 8: A descriptive model of cigarette epidemic in developed countries (Lopez et al. 1994) 
 Stages of the cigarette epidemic on entering its second century (Thune et al 2012): 
(Reprinted with permission from BMJ publisher group) 
 
1.3.2 Prevalence of smoking in the Nordic countries 
 
In 1920, Denmark had the highest prevalence of smoking in the Nordic countries. A report 
from 2006 showed the highest prevalence in Denmark and Norway (25 and 24, respectively), 
and the lowest prevalence in Sweden and Iceland (18). Direct comparisons of the smoking 
prevalence in Nordic countries are somewhat difficult as the data on smoking habits are 
collected in different age groups. However, in all of the Nordic countries a decreasing trend in 






1.3.3 Prevalence of smoking in Norway 
 
The trend of smoking prevalence for men current smokers has been different from that of 
women in Norway. The prevalence of smoking among men peaked at 65 % in the late 1950’s; 
and then decreased to 50% in 1975 and 33% in 1999. This decrease continued through 2007, 
when the prevalence of smoking among men was 50% lower than that in the 1970s. This is 
quite different from the corresponding figures of smoking prevalence among women. In 1954, 
the prevalence of smoking among women which was 23% in 1954, peaked at 37% in 1970 
and then stabilized to 32% for the rest of the century. After 2002, a decline in the prevalence 
of smoking was seen among women and by 2007 which is the end of our follow-up period; 
the prevalence was similar in both men and women (18;20;21). By the year 2013, 15% 
Norwegian men and women were current smokers (22). This smoking pattern is in accordance 
with the tobacco epidemic stages model suggested by Lopez et al. almost 20 years ago (16) 
which suggested that the smoking-attributed mortality for women, will in the same way as the 
smoking prevalence, lagged behind that of men and both will peak at a lower level than that 
of men. The difference in smoking habits is one of the main explanations for social 
inequalities in health in Norway. Recently, it has been reported that Norway is one of the four 
countries along with Canada, Iceland and Mexico that are successful in achieving reductions 
of smoking prevalence in both men and women by more than 50% (23). Figure 9 shows the 







Figure 9: Men and women current smokers aged 16-74 years old since 1973-2009 














1.4 Assessment of risk factors for colorectal cancer 
1.4.1 Non-modifiable risk factors 
Age 
Increased life span is one of the contributors for increasing number of cancer cases and CRC 
is no exception (24). CRC is common in older age groups: people aged 50 years and older 
accounting for more than 90% of cases and CRC incidence is low among people aged less 
than 50 years (25). However, recent trends show that CRC incidence is also increasing among 
those under 50 years of age (26;27). 
Gender 
As previously mentioned, CRC incidence and mortality rates are generally higher among men 
than women (6) and this difference may reach 35-40% higher in men compared to women(9). 
Differences by gender in CRC incidence are more obvious for rectal cancer which has a 
higher incidence among men. The reason for this difference is difficult to explain but may be 
partly due to exposures to different risk factors and hormones (28). 
Geographical variations and race 
CRC prevalence varies according to geographical locations and race. The number of CRC 
cases is declining in the United States, and stabilizing in most of Northern and Western 
Europe (25;29). Although, rates are low in Asia and Africa, CRC incidence is increasing in 
countries like Japan, Singapore and most Eastern European countries. 
Adenomatous polyps 
Adenomatous polyps are recognized precursor lesions of CRC and are common after 50 years 
of age. They represent almost two-thirds of colorectal adenomas and have a high potential to 
progress to malignancy. The majority of CRC develop from adenomatous polyps through a 
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series of genetic changes (30) but only around 10% of adenomatous polyps develop into 
cancer (31). An association between cigarette smoking and adenomatous polyps has been 
reported recently and it was suggested that smoking could play an important role in both the 
formation and aggressiveness of adenomatous polyps (32;33).  
Inflammatory bowel diseases 
Inflammatory bowel diseases (IBD) such as ulcerating colitis and Crohn’s disease might 
predispose to CRC development though these diseases account for very few cases of CRC in 
the general population and only around 15% of all CRC deaths occur among individuals with 
IBD (34;35). Factors such as early age at IBD diagnosis, longer duration of symptoms and 
severity of dysplasia and inflammation increase the risk of CRC. 
Family and personal history of colorectal cancer or adenomatous polyps  
A family history of CRC is a well-established risk factor (28) and is associated with an 
increased risk of the CRC (36). Individuals with a family history of CRC and colorectal 
adenomas mainly adenomatous polyps have higher risk of CRC (37). The risk of CRC is 
increases when a first degree relative has one or more colorectal adenomas mainly 
adenomatous polyps (38) and the risk is doubled when a first degree relative is affected with 
CRC. Similarly, individuals with multiple relatives affected with CRC who were diagnosed at 
a young age have a risk of CRC that is three to six times than that of general population (39). 
Almost 20% of all CRC cases have a close relative who have been diagnosed with the same 
cancer (40). Person who had CRC are more likely to develop it again in other areas of colon 
and rectum. This can occur even when the first cancer is removed completely. The risk further 
increases if the first cancer is diagnosed at 60 years of age or younger (9). Furthermore, 
person with previous adenomatous polyps are in increased risk of CRC and this is more 
probable if the polyps were multiple and were of large sizes (41). 
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Genetic risk factor 
The risk of CRC associated with hereditary conditions is about 5 to 10% (42). The two types 
of hereditary conditions are familial adenomatous polyps (FAP) and lynch syndrome, which is 
also known as hereditary non-polyposis colorectal cancer (HNPCC). The genes that mutate 
and lead to carcinogenesis have been identified in both of these conditions. MLH1 and MLH2 
are responsible for mutations in individuals with HNPCC (43) whereas APC genes are 
responsible for mutation in FAP (44). HNPCC is the most common of these genetic 
syndromes and accounts almost 2- 4% of CRC (45), whereas AFP accounts for less than 1% 
(46). 
 
1.4.2 Modifiable risk factors 
Physical activity and obesity 
The association between a high level of physical activity and decrease colon and rectal risk of 
cancer has been reported previously in a recent meta-analysis which included 52 cohort and 
case control studies (47). The study reported around a 20-30% decreased risk of colon cancer 
among physically active individuals compared with less active ones. Similarly, another meta-
analysis concluded that physical activity is associated with reduced risk of both proximal and 
colon cancer which did not differ by location (48). Lack of physical activity can also lead to 
obesity, another major risk factor for CRC (49), but a high level of physical activity can lower 
the risk of CRC even without the significant weight loss (50). Nevertheless, many studies 
have supported the notion that obesity leads to the development of CRC, and have reported 




Diet is a major modifiable risk factor for CRC. It has been reported that changes in dietary 
patterns can reduce the CRC burden by 70% (49;57). Diets that are high in fat and high meat 
consumption have been implicated in the development of CRC (49;58;59). Diets consisting of 
large amounts of red meat and highly refined carbohydrates increase the risk of CRC as do 
diets low in vegetables and fruits (50;60-62). 
Alcohol consumption 
The IARC has concluded that alcohol consumption is a potential risk factor for CRC (33). 
Indeed, alcohol consumption is one of the most important modifiable risk factors for all 
human cancers (63). Heavy alcohol consumption is linked to an increased CRC and could 
even give rise to CRC at younger age (8;64). Metabolic product of alcohol such as 
acetaldehyde is considered to be carcinogenic (65). Alcohol can also work as a solvent which 
could allow other carcinogenic molecules into the colon and rectum mucosa (66). Similarly, 
an individual with high alcohol consumption and a diet low in essential nutrients is more 
vulnerable to the carcinogenic effects of alcohol. Several meta-analysis and pooled studies 
carried out in different parts of the world reported an increased risk of CRC with high regular 
alcohol consumption (67-75). 
Medications, supplements and hormonal replacement therapy 
There is growing evidence that COX inhibitors such as aspirin, calcium supplements and 
hormonal replacement therapy (HRT) may have preventive effects towards the CRC (9;76;77) 
Calcium supplements have been shown to reduce the risk of recurrent polyps (78). The long-
term use of aspirin has been shown to have preventive effects on CRC (77;79) but it is not 
prescribed routinely for this purpose because of its side effects which includes gastrointestinal 
bleeding (9). Although, HRT has shown protective effects against CRC, it can increase the 
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risk for breast and other cancers, and therefore is not presently used for CRC prevention 
(76;77;79;80). 
 
1.5 Smoking and colorectal cancer  
Smoking is a major contributing factor to human carcinogenesis and is one of the most 
important modifiable risk factors for cancer and premature death worldwide (24). The main 
hazards of smoking are related to exposures such as age at smoking initiation, numbers of 
cigarettes smoked per day, smoking inhalation or type of cigarettes such as either tar and 
nicotine, or content or filter type (81). Cigarette smoke contains more than 7000 chemical 
compounds majority of which are carcinogens such as polycyclic aromatic hydrocarbons 
(PAH) and nitrosamines in addition to other promoters. These mixtures contribute to complete 
carcinogenesis in the mucosa of the colon and rectum (82). The carcinogenic effects of 
smoking could be initiated through multiple pathways such as DNA binding and mutations, 
oxidative stress, epigenetic changes, or inflammation (14). Figure 10 shows the pathway for 
causation of cancer via the carcinogenic effects of smoking. In the most recent monograph 
published in 2012 (33), and the report from the Unites States Surgeon General (15), the 
conclusion was that there is a casual association between smoking and CRC. The association 
between smoking and CRC risk has been shown to be dose-related (83-85). A longer exposure 
to or duration of smoking (35-40 years) has been shown to be associated with increased risk 
of CRC (86;87). The association between smoking and colorectal adenomas which are 




Figure 10: Pathway for causation of cancer by carcinogens in tobacco smoke 
(Reprinted from the United States Department of Health and Human Services (2004). The Health 
consequences of Smoking: A Report of the Surgeon General. Atlanta, GA: The United States 
Department of Health and Human Services, Center for Disease Control and Prevention, National 












2 Aims of the thesis 
 
The main aim of this thesis was to examine the association between smoking and CRC 
incidence and mortality overall and by subsites and gender. 
The specific objectives were: 
1. To investigate the association between smoking and the risk of colon cancer overall, 
and by localization and gender. 
2. To investigate the association between smoking and the risk of rectal cancer by 
gender. 
3. To examine the association between smoking and CRC mortality overall, by subsites 
and gender. 
4. To examine the association between different smoking exposures i.e., age at smoking 
initiation, numbers of cigarettes smoked per day, smoking duration and number of pack-years 
smoked and colon and rectal cancer by gender. 
5.  To examine the association between different smoking exposures i.e., age at smoking 
initiation, numbers of cigarettes smoked per day, smoking duration and number of pack-years 







3 Materials and Methods 
3.1 Study population 
The cohort included 652,792 Norwegians (49% men) born between 1897 and 1975, recruited 
from several Norwegian health screening surveys initiated by the National Health Screening 
Service (now included in the Norwegian Institute of Public Health). These surveys were 
conducted between 1972 and 2003 and are as follows: the Oslo study I (1972-1973), the 
Norwegian counties study (1974-1988), the 40 years cohort (1985-1999) and the Cohort of 
Norway (CONOR, 1994-2003).  
In all surveys included, information was gathered through questionnaires and a short health 
examination. The design and protocol of these surveys were very similar, but there were some 
modifications during different time periods, mainly in the questionnaires regarding questions 
on smoking, alcohol consumption, physical activity and other lifestyle factors. In most 
surveys, the attendees were given another supplementary questionnaire which they completed 
at home and mailed back in a pre-addressed stamped envelope. The participation rates for the 
different surveys varied from 56-88%. A flow chart with a detailed description of study 
participants has been provided below (Figure 11). 
The Oslo study I 
This survey was conducted in 1972-1973 among men living in the municipality of Oslo. Men 
aged 40-49 years in Oslo and a random sample of 7% of the general male population aged 20-
39 years were invited to participate in screening for tuberculosis and cardiovascular disease. 
About 30,000 men were invited and almost 18,000 attended the screening (i.e., a participation 
rate of approximately 60%). The participants answered one-page questionnaire which focused 
on symptoms of cardiovascular disease and diabetes, smoking habits and physical activity. 
This was one of the first large epidemiological studies of that period and became a model for 
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establishing other population based health studies in Norway later on. Height, weight and 
blood pressure were measured during screening using a standard procedure (88-91). 
The Norwegian counties study 
These surveys included participants of cardiovascular disease screening in three Norwegian 
counties (Finnmark, Sogn og Fjordane and Oppland) during three different time periods: 
1974-1978, 1977-1983 and 1985-1988. All residents aged 35-49 years as well as random 
sample of 10% of the general population aged 20-34 years were invited to a first screening. A 
second and third screening was carried out, and included a combination of previous cohort as 
well as new ones. Similar protocols and questionnaires were applied for these surveys. The 
attendance rates were 88%, 88% and 84% at the three screening rounds, respectively (91-93). 
The 40 years cohort 
These surveys included about 420,000 Norwegian men and women, and were carried out in 
all of the 19 counties of Norway in 1985-1999 for cardiovascular disease screening. Men and 
women aged 40-42 years were the largest invited population. Individuals aged 65-67 years 
were also invited to the first round of surveys in some of the counties (Nord-Trøndelag, Møre 
and Romsdal and Hordaland). The participation rate was 69% (94;95). Of all the surveys 
included in this thesis, the 40 years cohort had the largest number of participants. 
 
The Cohort of Norway  
CONOR is a very large collaborative project including regional data from 10 epidemiological 
studies conducted in 1994-2003 which have been merged into a national database (please 
refer to Table 1 for details of surveys included in CONOR). Standardized protocols, 
procedures and questionnaires were used together with a short health examination. The 
questions used in CONOR have been validated previously. The response rate varies across the 
surveys. The average response rate for the 10 different surveys in the CONOR study was 
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56%. Altogether, around 309,000 individuals were invited of which about 181,000 accepted 
to participate and provided consent (91;96;97). 
Table 1: List of different surveys included in the study 
 
 
Name of Survey Year 
Conducted  
Populations from  Surveys  
The Oslo study  I 1972 Oslo (only men) 1 
The Norwegian counties 
study  
1974-88 Oppland, Sogn og Fjordane, Finnmark 9 
40 years cohort 1985-99 All Norwegian counties included 19 
CONOR  
Tromsø Health Study IV 1994-95 Tromsø 1 
The second Nord-Trøndelag  
Health study (HUNT 2)  
1995-1997 Nord-Trøndelag   1 
Hordaland Health 
Study(HUSK) 
1997-99 Hordaland 1 
Oslo study II  2000 Oslo 1 
HUBRO( The Oslo Health 
Study) 
2000-2001 Oslo 1 
Oppland and Hedmark Health 
Study (OPPHED) 
2000-1 Oppland and Hedmark  1 
Tromsø Health Study V 2001 Tromsø 1 
I-HUBRO(The Oslo 
Immigrant Health Study) 
2002 Oslo 1 
Troms and Finnmark Health 
Study (TROFINN)  
2002 Troms and Finnmark 1 
MoRo II(The second part of 
the Romsås in Motion Study 
2003 Romsås 1 


































            
            
        
            
         







Figure 11: Detailed flowchart of participants from the different surveys 
 




counties study I 
(1974-1988) 
The 40 years cohort 
(1985-1999) 















men = 322,450 
women = 330,342 
Total = 652,792 
Excluded due to 
1. Emigration or deaths before the 
start of follow-up =1,009 
2. Prevalent cancer =11,476 
3. Missing smoking information 
= 6,299 
4. Missing information BMI 
=5,107 
5. Missing information physical 
activity =8,210 
6. Missing information education 
= 18,449 
men = 299,376 
women = 302,866  




3.1 Pooling Datasets 
After obtaining specified variables from each survey’s primary data using the unique key 
identifier for each participant, we created a standardized data base for the pooled analyses. 
There were total 833,871 registered observations including 181,079 doubles or more. For 
participants who took part in more than one survey, only the earliest survey was included. 
Variables common to all surveys were transformed to the same format. The variables in the 
CONOR study were adequately structured and this was taken as a reference for standardizing 
the questionnaires. All surveys had a baseline questionnaire, which included detailed 
assessments of smoking habits, physical activity, and other lifestyle factors. At the screening 
facility height and weight were measured in a standardized way by a trained person, which 
allowed us to calculate body mass index (BMI, kg/m2). Question on smoking habits were 
similar but not identical across all surveys. The questions asked about current and former 
daily smoking habits, smoking duration, average number of cigarettes smoked per day and in 
few surveys former smokers were asked about time since cigarette quitting. Only the CONOR 
study asked about age at smoking initiation. In the other surveys, this variable was estimated 
for both current (age at enrolment minus duration of smoking in years) and former (age at 
enrolment minus years since quitting and duration of smoking) smokers. We also found 
common formats for other variables such as menopause, menarche, HRT and alcohol 
consumption which were available only in the latest surveys such as 40 years III and IV and 
CONOR. Due to large missing in these variables which reached more than 50%, we were not 
able to use them in our main analysis. Detailed information on how the files were merged into 




3.3 Exposure information 
Participants who smoked daily were categorized as current smokers, and those who answered 
that they had smoked previously but not currently or if they answered the year since quitting 
smoking were categorized as former smokers. Current and former smokers were then 
combined into a single category called ever smokers. In Paper I, we further categorized ever 
smokers according to: age at smoking initiation (≤16, 17-19, 20-24, ≥25), numbers of 
cigarettes smoked per day (1-9, 10-19, ≥20), smoking duration in years (1-19, 20-29, 30-39, 
≥40) and number of pack-years smoked (i.e., number of cigarettes smoked per day, divided by 
20, multiplied by the duration of smoking in years) (0-9, 10-19, ≥20) . In Paper II and III, we 
categorized ever smokers by different measures of smoking exposure: age at smoking 
initiation (≤19, 20-24, ≥25), numbers of cigarettes smoked per day (1-9, 10-19, ≥20), smoking 
duration in years (1-19, 20-29, ≥30) and number of pack-years smoked (0-9, 10-19, ≥20). In 
all three papers, participants who were neither current nor former smokers were classified as 
never smokers. Participants were categorized into three groups based on their level of 
physical activity at enrolment: sedentary (reading, watching television, sedentary activity, or 
walking, bicycling <4 hours per week), moderate (walking, bicycling, and/or similar activities 
≥4 hours per week), and heavy (light sports or heavy gardening ≥4 hours per week, heavy 
exercise or daily competitive sports). The most recent information regarding duration of 
education was obtained from Statistics Norway and was used to assign subjects to one of three 





3.4 Follow-up and endpoints 
The study population comprised individuals who participated in of one of the four health 
surveys included in our thesis. We excluded participants who had emigrated or died before the 
start of follow-up n = 1,009 (50% women) and those with prevalent cancer n = 11,476 (62% 
women). We also excluded participants with missing information on either smoking exposure 
n = 6,299 (45% women) or on any of the co-variates [BMI, physical activity, education n = 
31,766 (50% women)]. Altogether 50,550 (48% women) participants were excluded leaving 
602,242 subjects (51% women) in the analytical cohort for all papers. 
We followed all participants aged 19–67 years at enrolment through a linkage to the Cancer 
Registry of Norway and the Central Population Register, utilizing the unique 11-digit personal 
identification number to identify all cancer cases, emigrations and deaths. The participants 
were linked to the Cancer Registry of Norway, the Norwegian Cause of Death Registry and 
the Central Population Register. The national registries have accurate and detail information 
regarding cancer incidence and mortality (98). The national registries are both accurate and 
virtually complete (98;99). The start of follow-up was set at 1 January of the year after the 
baseline questionnaire was completed. In Paper I, person-years were calculated from the start 
of follow-up to the date of colon cancer diagnosis, the date of any incident cancer diagnosis 
(except skin basal cell carcinoma), emigration, death, or the end of follow-up, i.e., December 
31, 2007, whichever occurred first. In Paper II, person-years was calculated from the start of 
follow-up to the date of rectal cancer diagnosis, the date of any incident cancer diagnosis 
(except skin basal cell carcinoma), emigration, death, or the end of follow-up, i.e. December 
31, 2007, whichever occurred first. In paper III, follow-up ended at the time of death from 
primary CRC cancer, death from any other cancer (except basal cell carcinoma of the skin), 




Colon and rectal cancer were classified according to the Seventh Revision of the International 
Statistical Classification of Diseases (ICD-7) (codes 153 and 154 respectively), and colon 
cancer was further categorized according to tumor location, i.e., proximal (codes 153.0/153.1) 
and distal (codes 153.2/153.3). Tumors that were overlapping (code 153.4), were specified as 
appendix (code 153.6), or were unspecified (code 153.9) were classified as “others” and were 
included in the analyses for the whole colon only. CRC mortality was classified according to 
ICD-9 and ICD-10. 
3.5 Statistical analyses  
We performed all analyses separately by gender. We used the t-test and χ2 test for 
investigating differences in the distribution of selected characteristics between cases and non-
cases and between ever and never smokers. The Cox proportional hazards model was used 
with age as the underlying time scale to estimate multivariate-adjusted hazard ratios (HR) 
with 95% confidence intervals (CIs) for the associations between different measures of 
smoking exposure age at smoking initiation, numbers of cigarettes smoked per day, smoking 
duration in years and number of pack-years smoked and colon cancer overall, and according 
to tumor location (Paper I), rectal cancer (Paper II) and CRC mortality (Paper III) with never 
smokers as the reference group. In Paper I, entry time was defined as age at enrolment and 
exit time was age at diagnosis of colon cancer, the date of any incident cancer diagnosis 
(except basal cell carcinoma), emigration, death, or the end of follow-up (31 December, 
2007), whichever occurred first. 
In Paper II, entry time was defined as age at enrolment and exit time was age at diagnosis of 
rectal cancer, the date of any incident cancer diagnosis (except basal cell carcinoma), 
emigration, death, or the end of follow-up (31 December, 2007), whichever occurred first. 
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In Paper III, entry time was defined as age at enrolment and exit time was age at death, 
emigration, or end of follow-up (31 December, 2007), whichever occurred first. 
The possible confounders included in the final models in Paper I, II and III, selected a priori, 
were age at enrolment (continuous), level of physical activity (sedentary, moderate and 
heavy), BMI (continuous), all at enrolment and duration of education in years (<10, 10-12, 
≥13). Tests for linear trends were obtained by creating an ordinal exposure variable with 
equally spaced scores and including it in the models with never smokers as the reference 
group. Test of heterogeneity by gender and its effect on the association between smoking and 
the risk of colon cancer overall, and by location, rectal cancer and CRC mortality were tested 
using Wald χ2 statistics in Paper I, II and III, respectively. Two-sided p-values <0.05 were 
considered statistically significant. All analyses were conducted using STATA version 12.0 
(Stata Corp., College Station, TX, USA).  
In all the papers, the same methods of statistical analysis were used; only the outcome 
variable differed. Outcome for Paper I was colon cancer, Paper II was rectal cancer and Paper 
III was CRC mortality.  
In all the papers, we re-analyzed the data excluding the 8,151 (99% men) participants who 
reported smoking only cigars or pipes. We had information on alcohol consumption for 37% 
(n = 221,748) of the participants. We did sensitivity analyses by gender for the main 
outcomes based on this population (49% men) with and without adjustment for alcohol 
consumption in all papers. 
3.6 Ethical aspects 
Oral or written informed consent was obtained from participants in the different surveys. 
Surveys carried out in 1995 and after had written consent. We also obtained approval from the 
respective steering committees to all the health surveys included. We obtained approvals from 
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the National Data Inspection Board, the Regional Committee for Medical Research Ethics 
(REK), the Norwegian Directorate of Health, Norwegian Tax Administration and Norwegian 
Public Health Institute. The data was handled in accordance with the permissions taken from 



















4 Results – summary of papers 
4.1 Paper I 
The increased risk of colon cancer due to cigarette smoking may be greater in women 
than men. 
In Paper I, we investigated the association between smoking and colon cancer overall, by 
location and gender. The study followed 602,242 Norwegian men and women and 3,998 
colon cancer cases (46% of cases in women). Women ever smokers had a 19% (HR = 1.19, 
95% CI = 1.09-1.32) and men ever smokers had 8% (HR = 1.08, 95% CI = 0.97-1.19) 
increased risk of colon cancer compared with gender specific never smokers. For all four 
dose-response variables examined, women ever smokers in the most exposed category of age 
at smoking initiation, (HR = 1.48, 95% CI = 1.21-1.81), number of cigarettes smoked per day 
(HR = 1.28, 95% CI = 1.06-1.55), smoking duration (HR = 1.47, 95% CI = 1.11-1.95), and 
pack-years smoked (HR = 1.33, 95% CI = 1.11-1.57) had a significantly increased risk of 
more than 20% for colon cancer overall and of more than 40% for proximal colon cancer 
compared with never smokers. Women ever smokers had a higher risk of proximal colon 
cancer compared to men ever smokers (Wald χ2, p = 0.02). 
Sensitivity analyses were carried out for participants with information on alcohol 
consumption which mainly included participants enrolled after 1995 (37% of total analytical 
cohort, n = 221,748). The corresponding risk estimates for women ever smokers were 16% 
(HR = 1.16, 95% CI = 0.86-1.74), 27% (HR = 1.27%, 95% CI = 0.82-1.51) and 11% (HR= 
1.11, 95% CI = 0.78-1.59) for colon, proximal colon and distal colon cancer, respectively. 
However, among men ever smokers risk estimates were (HR = 0.99, 95% CI = 0.78-1.25), 
(HR = 0.97, 95% CI = 0.75-1.64), (HR = 0.82, 95% CI = 0.68-1.15) for colon, proximal colon 
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and distal colon cancer, respectively. Risk estimates with and without alcohol adjustment did 
not differ significantly. 
The conclusion was that women smokers may be more susceptible to colon cancer and 
especially to proximal colon cancer than men smokers. 
 
4.2 Paper II 
Smoking increases rectal cancer risk to the same extent in women as in men: Results 
from a Norwegian cohort study. 
In Paper II, we examined the association between smoking and rectal cancer incidence by 
gender among 602,242 Norwegian men and women. During a mean follow-up of 14 years, 
2,176 cases (61% cases in men) were diagnosed with invasive rectal cancer. Both men and 
women ever smokers had a significantly increased risk of rectal cancer of more than 25% for 
men (HR = 1.27, 95% CI = 1.11-1.45) and women (HR = 1.28, 95% CI = 1.11-1.48) 
compared with gender specific never smokers. Men smoking ≥20 pack-years had an increased 
risk of rectal cancer of 35% (HR = 1.35, 95% CI = 1.14-1.58), whereas women showed an 
increased risk of 47% (HR = 1.47, 95% CI = 1.13-1.91) compared with gender specific never 
smokers. For both men and women, we observed significant dose-response associations with 
rectal cancer risk when looking at age at smoking initiation, number of cigarettes smoked per 
day, smoking duration and number of pack-years smoked and using never smokers as the 
reference group (p-trend<0.05). The test for heterogeneity by gender was not significant 
between smoking status and the risk of rectal cancer (Wald χ2, p value; current smokers = 
0.85; former smokers = 0.87 and ever smokers = 1.00).  
In the sensitivity analyses for participants, mainly enrolled after 1995, with information on 
alcohol consumption, the risk estimate of rectal cancer incidence was 13% (HR = 1.13, 95% 
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CI = 0.83-1.55) with alcohol adjustment and 12% (HR = 1.12, 95% CI = 0.82-1.54) without 
alcohol adjustment among men ever compared with men never smokers. The risk estimate 
was 37% (HR = 1.37, 95% CI = 0.99-1.92) with alcohol adjustment and 39% (HR = 1.39, 
95% CI = 1.00-1.94) without alcohol adjustment among women ever compared with women 
never smokers.  
In conclusion, increased risk of rectal cancer due to smoking is similar in women as in men. 
 
4.3 Paper III 
Cigarette smoking and colorectal cancer mortality among 602,242 Norwegian men and 
women. 
In Paper III, we examined the association between different measures of smoking exposure 
and CRC mortality overall and by subsites among 602,242 Norwegian men and women and 
2,333 CRC deaths (60% in men). There were 1,607 (57% in men) colon cancer and 726 (67% 
in men) rectal cancer deaths. Women ever smokers had a 22% (HR = 1.22, 95% CI = 1.06-
1.40) increased risk CRC mortality compared with women never smokers. Men ever smokers 
had a CRC mortality risk of 23% (HR = 1.23, 95% CI = 1.08-1.40) when compared with men 
never smokers. Women ever smokers had an almost 50% (HR = 1.49, 95% CI = 1.20-1.87) 
increased risk of mortality from proximal colon cancer compared with women never smokers.  
A test for heterogeneity by gender showed an increased risk of mortality from proximal colon 
cancer among women, which was statistically significant for ever smokers and former 
smokers (Wald χ2 = 0.02 and 0.04, respectively). It was also significant for former smokers 
and the risk of rectal cancer showing increased risk among men (Wald χ2 = 0.02). 
In the sensitivity analyses among participants with information on alcohol consumption (37% 
of total analytical cohort), the risk estimates of CRC mortality was (HR = 0.84, 95% CI = 
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0.60–1.18) and (HR = 1.25, 95% CI = 0.89–1.74) among men and women ever smokers 
respectively. Risk estimates with and without alcohol adjustment did not differ significantly. 
In conclusion, smoking is associated with increased CRC mortality both among men and 
women. The risk of rectal and proximal colon cancer mortality was more pronounced among 























5.1 Methodological issues 
A detailed discussion of the findings is presented separately in each paper. In the following 
chapter, discussions of those aspects which are applicable to this thesis in general are 
presented. Epidemiological studies primarily provide important information regarding the 
general population. The main purpose of such studies is to generalize the results to another 
target population and to establish the association between a risk factor and an outcome. In this 
regard, validity of the study is a very important issue. The validity of an epidemiological 
study can be divided into two groups: internal validity and external validity. 
 
5.1.1 Internal Validity 
Internal validity is defined as the true measure of the variable obtained for the study subjects 
and refers to the logical conclusions drawn from them. It deals mostly with the accuracy of 
observed results of the study. Internal validity is evaluated by determining whether the 
observed changes or outcomes can be attributed to the main exposure and not to other causes. 
Several factors can influence the validity of observed association between an exposure and an 
outcome (100;101). A major threat to internal validity could be lack of representativeness of 
the study population. The two major errors that can occur in epidemiological studies are 
random and systematic errors. Internal validity depends both on random error as well as 
systematic errors such as bias and confounding (100;101). Figure 12 shows the diagrammatic 





Figure 12: A systematic approach to bias 
(Source: Appraising the evidence: what is selection bias? Henderson M et al: 
Reprinted with permission) 
 
Random error can arises due to sampling variability and can be addressed by appropriate 
statistical hypothesis testing. Random error may lead to non-reproducibility of study results 
which in turn could weaken or restrict the association between an exposure and an outcome 
(100). A large sample size gives more precision to a study. In our study, the large sample size 
minimized the sampling error and thus increased the precision (100). We have also addressed 
the issue of random error by applying the appropriate statistical procedures. Our hypothesis 
was tested at the 5% alpha level and 95% confidence intervals were calculated. The null 
hypothesis was rejected at a less than 5% level. Another error encountered in epidemiological 
studies is systematic error. Epidemiological studies with a minimal systematic error have a 
high accuracy. These errors are independent of the size of the study and statistical significance 
Error 










does not suggest the absence of any bias (102;103). We consider the discussion of selection 
and measurement bias relevant in relation to our study. 
Selection bias (Paper I-III) 
Selection bias in cohort studies results from the process of selecting study participants and can 
arise due to systematic differences in selection criteria (100). The possibility of this bias arises 
when a study sample is not representative of the source population (104). However, it is also 
true that selection bias is less probable in cohort studies than other epidemiological studies as 
the outcome is not known at the time of enrolment (105). In our study, we had no possibility 
to control for differences between responders and non-responders as there was no information 
available for the non-responders. 
In all of the surveys included in our study, age was a major criterion for enrolling participants. 
Most of the men and women enrolled were between 40-45 years of age and a large group of 
participants were included from the 40 years cohort. The detail description of the study 
participants categorized by age group during the time of enrolment in different surveys is 
shown in table 2. The overall participation rate ranged from 56-88%. The attendance rate in 
CONOR was 56% (range 30-76%) whereas in the Oslo study I, it was approximately 60%. 
The participation rate for the Norwegian counties study remained between 78-90%. In 40 
years cohort, the overall response rate was 69% but during 1994-99, the participation rate 

























16-30  869 9,778 740 9,492 20,879 (3.5) 
31-39  689 20,216 652 23,873 45,430 (7.5) 
40-44  4,782 29,282 364,285 25,583 423,932(70.4)  
45-50  9,506 23,458 5,281 16,675 54,920 (9.1) 
≥50  1,100 752 13,809 41,420 57,081 (9.5) 
Total 16,946(3) 83,486(14) 384,767(64) 117,043(19) 602,242  
 
Non-response bias is always a major issue in large longitudinal epidemiological studies like 
ours and declining participation rate is one of the major problems. However, low participation 
rates do not always indicate a high level of bias. Indeed, there has been very little evidence of 
substantial bias as a result of non-response and non-response introduces less influence on 
exposure-disease associations (106-108). Furthermore, we had a similar proportion of men 
and women participants in our study. A total of 50,550 participants excluded, 48% of which 
were women due to missing covariates. Thus, our study had a same proportion of men and 
women excluded due to the missing data. Those excluded group were similar to the analytical 
cohort in regards to their level of education and physical activity. Incidence rates for colon 
and rectal cancer among excluded group were also similar to the analytical cohort. 
Furthermore, smoking prevalence among participants from different health surveys in our 





Figure 13: The prevalence of current smokers included in surveys by gender 
 
 













Information bias (Paper I-III) 
Information bias is also known as observation, classification or measurement bias and arises 
from incorrect determination of an exposure, an outcome, or both (109). Measurements bias 
occurs when exposures and outcome variables are incorrectly measured (100). In the different 
surveys included in our study, height and weight were measured according to the standard 
procedure to minimize the measurement errors. There were some differences in the 
measurement of exposures variable but we minimized these differences by finding a common 
format during the merging of the datasets. Smoking history was obtained at study enrolment, 
and so was not subject to recall bias. Furthermore, smoking habits change; current smokers 
could have stopped smoking whereas never smokers may have started smoking. Our analysis 
was based on ever and never smokers, thus only the status of never smokers could have 
changed during follow-up. In addition to this, very few Norwegians start to smoke after the 
age of 30, and the mean age at enrolment for our study is more than 40 years, thus minimizing 
this type of bias. We assume that the possibility of information bias in our study is limited. 
Confounding and statistical analyses (Paper I-III) 
Confounder is defined as a variable which is associated with main exposure variable but at the 
same time an independent risk factor for the dependent variable (100;101). As a confounding 
variable is associated with the exposure and also with outcome but does not stand in the 
intermediate pathway in the chain of causation between an exposure and an outcome (109), it 
leads to the mixing or blurring of effects. This is one of the major challenges of an 
observational study as it can either attenuate or inflate an association between an exposure 
and an outcome. In a way, confounder is similar to bias but it can be controlled by 
stratification and adjustment in multivariate models. The magnitude of confounding can be 
evaluated by comparing crude and adjusted effect measure. Age and gender are almost always 
potential confounders (100;101). Our analyses were stratified by gender and hazard ratios 
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(HRs) and 95% CI were estimated by fitting Cox proportional hazard models where age was 
the primary time variable. In Papers I, II and III, age, BMI, physical activity at enrolment and 
duration of education were the confounders based on a priori, and were controlled for when 
estimating the association between smoking and colon and rectal cancer incidence and CRC 
mortality. The other important covariates that are established risk factors for CRC, such as 
alcohol consumption, HRT, diet such as red meat and COX inhibitors such as aspirin could 
not be adjusted for in the main analyses. Information on alcohol consumption was missing on 
more than 60% of the total participants whereas information on HRT was missing in more 
than 70% of total women. It has been reported that women could have protective hormonal 
effects until menopause from HRT which delay or protect them from development of CRC 
(76). The use of HRT declined after there was growing evidence that it could be risk factor for 
breast cancer and other cardiovascular disease (110). Similarly, we lacked information on 
molecular data and CRC screening, as it was not common in Norway when the surveys 
included in our study were conducted. In addition to this, the information on staging of CRC 
was also not available. Cigar and pipe smoking may have less potential to be confounders and 
this could be the reason our sensitivity analyses excluding those smoking only cigar and pipe 
did not materially change the estimates (33). We also performed the sensitivity analyses 
among participants who had information on alcohol consumption, with and without alcohol 
adjustment. Only 37% of the total cohort (48% men) had information on alcohol 
consumption. Our sensitivity analyses including only those with information on alcohol 
consumption, risk estimates increased among women and but decreased among men ever 
smokers for rectal cancer incidence as well as for CRC mortality compared to risk estimates 
for the main cohort. For colon cancer, the estimates were more or less similar for women but 
decreased among men compared to risk estimates for the main cohort. However, the results 
did not change materially with and without alcohol adjustment in this sub cohort either among 
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men or women indicating that the lack of alcohol intake in the main cohort might not be a 
major limitation. However, the interpretation of our sensitivity analyses should be done with 
caution as they included fewer cases, younger participants with less follow-up time than in the 
main cohort. We should be very cautious to interpret the results of our sensitivity analyses as 
we lost a large number of cases and follow up time period (>75%). The studies such as Oslo 
study I, the Norwegian counties study and earlier rounds of 40 years cohort did not have the 
information on alcohol consumption. It is also true that the alcohol consumption is higher 
among men than women in Norway (111). Thus, the lack of adjustments of alcohol 
consumption in our main cohort analyses is likely to have inflated the estimates among men 
more than women and thus attenuated the gender difference. 
The statistical approach to use Cox proportional hazards analysis with age as primary time 
variable to examine the association between smoking and CRC incidence and mortality was 
considered appropriate to answer the research questions in Papers I, II and III. Modelling the 
events using a proportional hazards model with age as the time scale has been recommended 
as an appropriate method in large health surveys with disease or death as outcome. 
Furthermore, it has been suggested that using age as a primary time variable is more 
meaningful and less restrictive than using time on study as the time scale (112). 
 
5.1.2 External validity 
External validity is the probability of generalizing the study results to a wider population. This 
can be also referred as the possibility, or the degree to which the results of the study is 
applicable to different population in other places and at different time periods (100;101;113). 
Internal validity is always a pre-requisite for external validity. Although, we had some issues 
with internal validity, we are convinced that it did not distort our results. Our study includes 
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very large participants from all over Norway. The separate health surveys included in our 
study have well-validated datasets. In general, it is difficult to generalize the study results to a 
wider population but we assume our study conclusion could be generalized to the Caucasian 
and Western population. 
 
5.2 Discussion of the main results 
The main findings are discussed in the respective papers (Papers I-III) in detail. Despite some 
methodological limitations in the three papers, they have contributed to further support the 
fact that smoking increases CRC incidence and mortality among both men and women. The 
discussion below is focused on the main messages of the three papers regarding the 
association between smoking and CRC. 
 
5.2.1 Gender differences in smoking related colon cancer  
The findings from Paper I is in agreement with IARC and United States Surgeon General’s 
recent conclusion that cigarette smoking is associated with colon cancer (15;33). Incidence 
rates are more important and reliable indicator of trends in disease occurrence than mortality 
rates as incidence is not influenced by changes in treatment and survival (6). The main 
difference in CRC in general observed by gender is due to the higher incidence of rectal 
cancer in men than women. There is not much difference in incidence rates of colon cancer 
between men and women in Norway. 
There are gender reported differences in incidence of colon cancer by location (i.e. proximal 
vs. distal colon cancer). Some studies have concluded in general that the risk of distal colon 
cancer is lower among women than in men (114-116). Previous knowledge regarding 
smoking and colon cancer incidence in general varies by gender. Some studies reported that 
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the association between smoking and colon cancer may be stronger in men as compared to 
women (75;117;118). However, these reports could be attributed to the low prevalence of ever 
smoking women. On the other hand, the results of the studies among women only (119-122) 
reported findings which were more or less comparable to men for both colon as well as rectal 
cancer. A recent study from Europe which included men and women from ten European 
countries reported the risk estimates by subsites and indicated that the ever smokers have an 
increased risk of colon cancer, which was especially pronounced in the proximal than in the 
distal colon (123). However, this study did not report the risk estimates by gender. Another 
study of Norwegian women reported an increased risk of proximal than distal colon cancer 
among women ever smokers (119). A study among postmenopausal women in the United 
States aged 55-69 years at baseline also reported an increased risk of proximal than distal 
colon cancer (120). Furthermore, smoking has been shown to be associated with a higher 
incidence proximal colon cancer among Caucasian women in the United States as compared 
with distal colon cancer (124). A study from Japan which was conducted both among men 
and women and included around 400 colon cancer, reported the risk estimates by gender and 
the findings were insignificant increase risk of colon cancer among both men and women ever 
smokers (125). Increased risk of proximal colon cancer among women smokers has been 
reported to be related with epigenetic changes which are induced by tobacco related 
carcinogens (120). It has also been suggested that gender-related differences in hormonal 
factors (126) or susceptibility to tobacco related carcinogens (127) could have influenced the 
observed different associations for proximal and distal colon cancer by gender (120) which 
might explain the reason for increased risk of proximal colon cancer among women smokers 
compared to men smokers. There are not many prospective cohort studies examining the 
association between smoking and colon cancer by location and gender in detail. Our study is 
among the very few studies with a very large numbers of incidence cases as well as a large 
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proportions of ever and never smokers that examined the association between smoking and 
colon cancer incidence by location and gender. The findings from our study suggested that 
women smokers maybe more prone to colon cancer especially for proximal colon cancer than 
men smokers. Our findings could be a strong warning for the women smokers who could be 
more vulnerable to smoking related colon cancer than men. This may have important clinical 
and research implications if further confirmed by other large population based 
epidemiological studies.  
 
5.2.2 Smoking related risk of rectal cancer among women is same as in men 
The epidemiologic evidence supports that it takes decades before the increased risk of rectal 
cancer appears and that smoking plays an important role in early carcinogenesis both among 
men and women (15;86;87). The incidence rate of rectal cancer is higher among Norwegian 
men compared to Norwegian women and as mentioned earlier this is the main reason for 
gender difference in CRC incidence rate in general. The difference in rectal cancer incidence 
rate was almost 1.5 fold higher among Norwegian men in the beginning of our study period 
and the situation remained similar until the end of our study period. In the latest report from 
Norwegian Cancer Registry, this difference is also valid for the present time period (10). Risk 
patterns were shown to be generally consistent for colon and rectal cancer (73;75). However, 
some studies reported a stronger dose response association between smoking and rectal rather 
than colon cancer (8;118;121;122;128). Recent meta-analyses also concluded that the ever 
smokers are in increased risk of rectal cancer (70;83-85), however these studies did not 
present the risk estimates by gender. Our findings are in accordance with findings of these 
meta-analyses regarding higher risk estimates for rectal than colon cancer. In a study done 
among women in the United States, an increased risk of rectal cancer but not colon cancer 
was observed among ever smokers (121). Another study done among Norwegian women 
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reported the higher risk for colon than rectal cancer among smokers (119). Furthermore, two 
recent studies, one from 10 European countries including almost half a million men and 
women and 950 rectal cancer cases (123) and another from Asia including 329 rectal cancer 
cases (64) are the largest cohort study done before ours examining the association between 
smoking and rectal cancer. The study from 10 European countries found a non-significant 
increase in rectal cancer; however the later study found a significant increased risk of rectal 
cancer among ever smokers. These studies did not report the risk estimates by gender. A few 
studies from Japan examined the association between smoking and rectal cancer, however 
they included 200 or less cases (73;74). Furthermore, these studies showed an insignificant 
increased risk of rectal cancer among men and women ever smokers. Our study is one of the 
few to examine the association between smoking and rectal cancer by gender in detail. Our 
findings indicated that there is a significant increased risk for rectal cancer among men and 
women ever smokers. Furthermore, the findings also concluded that the risk was similar for 
women as in men. This could be a very important finding as the impact of cigarette smoking 
could be reflected in future rectal cancer incidence among women as the smoking epidemic 
among women began later than men, and as for colon cancer, rectal cancer also has a long 
latent period. 
5.2.3 Smoking increases the risk of CRC Mortality 
In Paper III, we found increased risk of CRC mortality both among men and women ever 
smokers. We concluded that the risk of rectal cancer mortality was higher among men 
smokers and risk of proximal colon cancer mortality was higher among women smokers. 
Similarly, the increased mortality risk by subsites was slightly more pronounced among 
current smokers compared with the former smokers both among men and women. The higher 
risk of rectal cancer mortality among men ever smokers and increased proximal colon cancer 
mortality risk among women ever smokers could be a mere reflection of the colon and rectal 
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cancer incidence in our cohort. As mentioned earlier, smoking is one of the major preventable 
causes of death worldwide. Mortality from different diseases has been decreased in last 
decades due to early diagnosis and treatment; however current smokers have an increased risk 
of mortality compared to never smokers. Recently, two meta-analyses also reported that the 
risk of CRC mortality was higher among current than former smokers (83;84). Long term 
smoking is associated with an increased risk of CRC mortality both among men and women 
(15). Furthermore, increased mortality among current smokers could be due to possible 
differences in health behaviours. A recent report from the United States Surgeon General 
concluded that there is a sufficient evidence to infer a causal relationship between cigarette 
smoking and increased all-cause and cancer-specific mortality (15). Quitting smoking can 
decrease the mortality burden and CRC patients should be encouraged to quit smoking as 
smoking can lead to poorer response to cancer treatment (129). Furthermore, the relationship 
between smoking and mortality is stronger than before and recommendations encouraging 













The main aim of this thesis was to examine the association between smoking and CRC 
incidence and mortality overall and by subsites and gender. 
The conclusions to be drawn from the studies are: 
1. Smoking increased the risk of colon cancer among both men and women. The 
increased risk of colon cancer especially proximal colon cancer due, to smoking may be 
greater in women than men. 
2. Smoking increased the risk of rectal cancer among both men and women. The risk was 
similar for women as for men. 
3. Smoking increased the risk of CRC mortality among both men and women. The risk 
of rectal and proximal colon cancer mortality was most pronounced among men and women 
ever smokers, respectively.  
4.  The observed smoking related increased risk in colon and rectal cancer was dependent 
on different smoking exposures such as age at smoking initiation, number of cigarettes 
smoked per day, duration of smoking and pack years smoked both among men and women. 
5.  The observed smoking related increased risk in CRC mortality was dependent on 
different smoking exposures such as age at smoking initiation, number of cigarettes smoked 





7 Implications for public health practice and further 
perspectives 
 
CRC is one of the major public health problems in Norway. Our findings are consistent with 
the latest report from the IARC (1) and the United States Surgeon General (15) regarding the 
association between smoking and CRC. Smoking is possibly the most important modifiable 
risk factor of CRC. Detailed knowledge about the adverse harmful effects of smoking is 
important for general public health and future strategy planning. Additional strict rules against 
tobacco companies and tobacco sales should be implemented. The general population should 
be made aware of the possible harmful effects of smoking on the risk of CRC and younger 
age groups should be given special attention regarding smoking cessation and encouraged not 
to start smoking. Since women may be more vulnerable to the carcinogenic effects of 
smoking in relation to CRC, women-oriented awareness of harmful effects of smoking should 
be initiated. Current smokers should be encouraged to quit since the comorbid situation is 
increased among current smokers. More emphasis should be placed on taxes and price 
policies in the control of tobacco use to improve public health. Furthermore, CRC screening 
programme could be very helpful for early diagnosis and treatment. 
As there is a long latent period between smoking and risk of CRC, an investigation with a 
longer follow up period could reveal more exact risk estimates. Future studies should focus on 
the replication of the present findings and it will be very important to conduct these studies 






In Paper I:  
For the excluded men and women, the overall incidence of colon cancer was 53 and 59 per 
100, 000 person-years, respectively.  
The overall incidence of colon cancer among men and women was 49 and 44 per 100, 000 
person-years, respectively. 
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VARIABLE SPØRRESKJEMA NORSK (NORWEGIAN)
EGEN HELSE





a2_1 to a2_10 2. Har du eller har du hatt?








a4 3. Har du i løpet av siste året vært plaget med smerter og/eller 
stivhet i muskler og ledd som har  vart i minst 3 måneder sammenhengende?
Ja 
Nei
a5_1 to a5_7 4. Har du de to siste ukene følt deg:









a6_1 to a6_2 5a. Hvordan har din fysiske aktivitet i fritiden vært det siste året?
 Tenk deg et ukentlig gjennomsnitt for året. Arbeidsvei regnes som fritid.
Timer per uke i gjennomsnitt






a6_3 5 b. Angi bevegelse og kroppslig anstrengelse i din fritid. Hvis aktiviteten  
varierer meget f.eks mellom sommer og vinter, så ta et gjennomsnitt.  
Spørsmålet gjelder bare det siste året.
(Sett ett kryss i den ruta som passer best)
Lese, ser på fjernsyn eller annen stillesittende beskjeftigelse?
Spaserer, sykler eller beveger deg på annen måte minst 4 timer i uka?
(Her skal du regne med gang eller sykling til arbeidsstedet, søndagsturer m.m)
Driver mosjonsidrett, tyngre hagearbeid e.l?
(Merk at aktiviteten skal vare minst 4 timer i uka)
Trener hardt eller driver konkurranseidrett regelmessig og flere ganger i uka
RØYKING
a7_2 6 . Hvor lenge er du vanligvis daglig til stede i røykfylt rom? 
Sett 0 hvis du ikke oppholder deg i røykfylt rom.
Antall timer………..
a7_3 7. Røkte noen av de voksne hjemme da du vokste opp?
Ja
Nei
a7_4 8. Bor du/har du bodd sammen med noen daglig-røykere etter fylte 20 år?
Ja
Nei
a8_0 to a8_3 9. Røyker du selv ?




a9 10. Hvis du har røykt daglig tidligere, hvor lenge er det siden du sluttet?
………år
a10 11. Hvis du røker daglig nå eller har røykt tidligere: 
Hvor mange sigaretter røyker eller røykte du vanligvis daglig?
Antall sigaretter…………….
a11 12. Hvor gammel var du da du begynte å røyke?
………..år
a12_1 13. Hvor mange år til sammen har du røykt daglig ?
…………..år
KAFFE, TE OG ALKOHOL
a13_1 to a13_2 14.a Hvor mange kopper kaffe drikker du daglig?
a13_4 Sett 0 hvis du ikke drikker kaffe daglig
Kokekaffe, antall kopper………….
Annen kaffe, antall kopper………..




Annen kaffe (espresso og lignende)
Drikker ikke kaffe
a13_9 to a13_10 14c. Hvor mange kopper kaffe/te drikker du daglig? 
Sett 0 hvis du ikke drikker kaffe/te daglig
Antall kopper kaffe………….
Antall kopper te…………
a14_1 and a14_1_2 15 a. Hvor mange ganger i måneden drikker du vanligvis alkohol? 
(a14_1 made of 14_1_1 Regn ikke med lettøl. Sett 0 hvis mindre enn 1 gang i måneden.
and 14_1_2) Antall ganger………….
a14_1 and a14_1_1 15 b. Omtrent hvor ofte har du i løpet av det siste året drukket alkohol?
(a14_1 made of 14_1_1 (Lettøl og alkoholfritt øl regnes ikke med)
and 14_1_2) 4-7 ganger i uka
2-3 ganger i uka            
Ca 1.gang i uka
2-3 ganger pr måned
Omtrent1 gang i mnd.              
Noen få ganger siste år
Har ikke drukket  alkohol siste år       
Har aldri drukket alkohol
a14_4_1, a14_5_1 16 a. Hvor mange glass øl, vin eller brennevin 
drikker du vanligvis i løpet av to uker? 
Regn ikke med lettøl. Sett 0 hvis du ikke drikker alkohol.
Øl…..glass   Vin…..glass    Brennevin…..glass
Til dem som har drukket siste år
a14_2 16 b. Når du har drukket alkohol, hvor mange glass/og eller drinker 
har du vanligvis drukket?
Antall………….
a14_3 16 c. Omtrent hvor mange ganger i løpet av det siste året har du drukket så mye 
som minst 5 glass og/eller drinker i løpet av et døgn?
Antall ganger………..
a14_4, a14_5, 16 d. Når du drikker alkohol, drikker du da vanligvis: (Sett ett eller flere kryss).
a14_6, a14_6_1 Øl                 Vin                         Brennevin                 




a15, a15_2 18 a. Hvilken utdanning er den høyeste du har fullført?
(made of a15_1 and a15_2) Mindre enn 7 år grunnskole
Grunnskole 7-10 år, framhaldsskole, folkehøyskole
Realskole, middelskole, yrkesskole, 1-2 årig videregående skole
Artium, økonomisk gymnas, allmennfaglig retning i videregående skole
Høgskole/universitet, mindre enn 4 år
Høgskole/universitet, 4 år eller mer
a15, a15_1 18 b. Hvor mange års skolegang har du gjennomført?
(made of a15_1 and a15_2) (Ta med alle år du har gått på skole eller studert)
Antall år………….
SYKDOM I FAMILIEN
a16 19. Har en eller flere av foreldre eller søsken hatt hjerteinfarkt (sår på hjertet) 




b15_1 to b15_30 20. Kryss for de slektninger som har eller har hatt noen av sykdommene:








Alder da de fikk sukkersyke
LOKALMILJØ OG BOLIG
b1 21. I hvilken kommune bodde du da du fylte 1 år? 
Hvis du ikke bodde i Norge, oppgi hvilket land i stedet for fylke.
………………………..






b3 23. Hvor stor er din boenhet?
………m2
b29 24. Er det heldekkende tepper i stua?
Ja                    Nei
b30 25. Er det katt i boligen?
Ja          Nei
FAMILIE OG VENNER
Sjekke 26a. Hvem bor du sammen med? Sett ett kryss for hvert spørsmål og angi antall.
                                                    Ja                    Nei                    Antall
Ektefelle/samboer
Andre personer over 18 år
Personer under 18 år




                                                        Ja                    Nei                    Antall
Ektefelle/samboer
Andre personer, 18 år og eldre
Personer under 18 år
b4_7 and b4_8 26 c (kun på eldreskjema) 
Bor du ? Sett kryss
Hjemme
Institusjon/bofellesskap
Bor du sammen med? 
                                      Ja                                 Nei
Ektefelle/samboer?
Andre personer? 
b31 27. Hvor mange av barna har plass i barnehage?
………..
b5 28. Hvor mange gode venner har du? Regn med de du kan snakke fortrolig 
med og som kan gi deg hjelp når du trenger det? 
(Tell ikke med de du bor sammen med, men ta med andre slektninger)
…………………….
b6 29. Føler du at du har nok gode venner?
Ja
Nei
b7 30. Hvor ofte tar du vanligvis del i foreningsvirksomhet som for eksempel 
syklubb,  idrettslag, politiske lag, religiøse eller andre foreninger?
Aldri, eller noen få ganger i året
1-2 ganger i måneden (før år 1996), 1-3 ganger i måneden (etter år 1996)
Omtrent 1 gang i uken
Mer enn en gang i uken
ARBEID





b9 and b9_1 32a. Hvor mange timer lønnet arbeid har du i uka?
……………….timer




b10_1, b10_2, b10_3 33. Mottar du noen av følgende ytelser?
b10_4, b10_5, b10_6 Sykepenger (er sykemeldt)
b10_7 Alderstrygd, førtidspensjon (AFP) eller etterlattepensjon
Rehabiliterings-/attføringspenger
Uførepensjon (helt eller delvis)
Dagpenger under arbeidsledighet
So1sialhjelp/stønad
Overgangsstønad for enslige forsørgere
b11 34. Har du skiftarbeid, nattarbeid eller går vakter?
Ja
Nei
b12 35. Hvis du er i lønnet eller ulønnet arbeid, hvordan vil du beskrive arbeidet ditt?
For det meste stillesittende arbeid?
(f.eks1 skrivebordsarbeid, montering)
Arbeid som krever at du går mye?
(f.eks ekspeditørarbeid, lett industriarbeid, undervisning)
Arbeid der du går og løfter mye?
(f.eks postbud, pleier, bygningsarbeider)
Tungt kroppsarbeid?(f.eks skogsarbeid, tungt jordbruksarbeid, tungt bygningsarbeid)
b32 36. Kan du selv bestemme hvordan arbeidet ditt skal legges opp? (Sett bare ett kryss)
Nei, ikke i det hele tatt
I liten grad
Ja, stort sett
Ja, det bestemmer jeg selv
b33_1, b33_2, b33_3 37a. Har du noen av følgende yrker ?
(heltid eller deltid) Sett kryss for hvert spørsmål




b33_4, b33_5 37b. Hvilket yrke/tittel har eller hadde du på dette arbeidsstedet? 
(spørsmålet henviser til et mellomliggende spørsmål (ikke CONOR)om 
den virksomhet man har arbeidet i lengst tid siste 12 mnd)
(For eksempel; sekretær, lærer, industriarbeider, barnepleier, møbelsnekker, 
avdelingsleder, selger sjåfør e.l)
Yrke………………………………………………
SYKDOM OG SKADER
b13_1, b13_2, b13_3 38. Har du noen gang hatt: 
b13_4, b13_5, b13_6 Sett et kryss for hvert spørsmål. Oppgi også alder ved hendelsen. 
b13_7, b13_8 Hvis det har skjedd flere ganger, hvor gammel var du siste gang.




Skade som førte til syke-
husinnleggelse
b14_1, b14_2, b14_3 39. Har du eller har du hatt?
b14_4, b14_5 Kryss av ja eller nei for hvert spørsmål





Psykiske plager som du har søkt hjelp for
b17 40. Hoster du omtrent daglig i perioder av året?
Ja                     Nei
b18 41. Hvis ja:
Er hosten vanligvis ledsaget av oppspytt?
Ja                     Nei
b19 42. Har du hatt slik hoste så lenge som i en 3 måneders periode i 
begge de to siste år?
Ja                     Nei
b20 43. Hvor ofte er du plaget av søvnløshet?
Aldri, eller noen få ganger i året
1-2 ganger i måneden (før år 2000), 1-3 ganger i måneden (etter år 2000)
Omtrent 1 gang i uken
Mer enn 1 gang i uken
b21 44. Har du siste året vært plaget av søvnløshet 
som har gått utover arbeidsevnen?                             Ja                      Nei
BRUK AV MEDISINER
b16_1, b16_2 45. Bruker du?
                                                    Nå              Før, men  ikke nå          Aldri brukt
Kolesterolsenkende medisin 
Medisin mot høyt blodtrykk
b16_19 to b16_24 46a. Har du i løpet av det siste året brukt noen av følgende 
midler daglig eller nesten daglig? 
Angi hvor mange måneder du brukte dem. Sett 0 hvis du ikke har brukt noen av midlene.
Legemidler
Smertestillende                                          ………mnd.
Sovemedisin                                               ………mnd.
Beroligende midler                                    ………mnd.
Midler mot depresjon                                ………mnd.
Allergimedisin                                           ………mnd.
Astmamedisin                                            ………mnd.
Med medisiner mener vi her medisiner som er kjøpt på apotek. 
Kosttilskudd og vitaminer regnes ikke med.
b16_3 to b16_8 46 b. Hvor ofte har du i løpet av de siste 4 ukene
brukt  følgende medisiner?
(Sett ett kryss per linje)
                                         Daglig            Hver uke,               Sjeldnere enn            Har ikke brukt 






Annen medisin på resept
b16_9_1 to b16_18_3 46c. Fyll inn navn på medisin, årsak til bruk og tiden den ble brukt fra sp 46b
 Navn på medisin                 Grunn til bruk                    Hvor lenge brukt 








b16_25 to b16_27 47 a. Har du i løpet av det siste året brukt noen av følgende midler 
daglig eller nesten daglig?
Angi hvor mange måneder du brukte dem. Sett 0 hvis du ikke har brukt noen av midlene.
Jerntabletter                                           ………mnd.
Vitamin D-tilskudd                                 ………mnd.
Andre vitamintilskudd                            ………mnd.
Tran                                                       ………mnd.
b16_28, b16_29 47 b. Bruker du følgende kosttilskudd?





RESTEN AV SKJEMAET SKAL BARE BESVARES AV KVINNER
b22 48. Hvor gammel var du da du fikk menstruasjon første gang?
………..år
b23 49. Hvis du ikke lenger har menstruasjon, hvor gammel var du da den sluttet?
………..år
b24 50. Er du gravid nå?
Ja                     Nei                    Usikker                Over fruktbar alder
b25 51. Hvor mange barn har du født tidligere?
…………barn
b26_1 to b26_12 52. Hvis du har født, fyll ut for hvert barn barnets fødselsår og omtrent antall 
måneder du ammet hvert barn.







b27_1 to b27_4 53. Bruker du eller har du brukt:
                                                       Nå                 Før                   Aldri
P-pille (også minipille)
P-sprøyte
Hormonspiral (ikke vanlig spiral)
Østrogen (tabletter eller plaster)
Østrogen (krem eller stikkpiller)
54. Hvis du brukte p-pille, minipille, p-sprøyte, hormonspiral eller østrogen,














2. Do you have, or have you had?








3. Have you during the last year suffered from pain and/or
stiffness in muscles and joints that have lasted for at least 3 months ?
Yes
No
4. Have you in the last two weeks felt :









5a. How has your physical activity during leisure time been over the last year ? 
Think of your weekly average for the year. Time spent going to  or fromworkk counts as leisure time 
Hours per week                     
                                                      None     Less than 1     1-2     3 or more
Light activity
 (not sweating or out of breath )
Hard physical activity
(sweating/out of breath )
5 b.  Please note physical activity during the past year in your spare time. 
If activity varies between summer and wintertime,   
note a mean value.
(Tick one only)
Reading, watching TV or any other sedentary activity?
Walking, cycling, or other activity, other for at least 4 hours a week?
(Count also walking back and forth from work)
Light sports, heavy gardening?
(At least 4 thours perweek)
 Hard exercise, competitive sports? Regularly and several times a week
SMOKING
6 . How many hours a day do you normally spend in smoke-filled rooms? 
Write 0 if you don`t spend time in smoke-filled rooms
Number of hours………..
7. Did any of the adults smoke at home when you grew up?
Yes
No
8. Do you now, or have you ever lived together with a daily smoker after the age of 20 years?
Yes
No
9. Do you smoke ?




10. If you previously smoked daily, how long is it since you quit?
………number of years
11. If you smoke daily now or previously: 
How many cigarettes do you,or did you usually smoke per day?
Number of cigarettes…………….
12. How old were you when you began smoking?
………..year
13. How many years in all have you smoked daily ?
…………..years
COFFEE, TEA AND ALCOHOL
14.a How many cups of  coffee do you usually drink daily ?
Write 0 if you do not drink coffee daily
Boiled coffee (coarsely ground), number……
Coffee other, number………..
14.b What type of coffee do you usually drink?
Please tick
Filter/instant coffee
Boiled coffee (coarsely ground)
Other (espresso etc)
Do not drink coffee
14c. How many cups of  coffee/tea do you usually drink daily? 
Write 0 if you do not drink coffee/tea daily
Number of cups with coffee………….
Number of cups with tea…………
15 a. How many times a month do you usually drink alcohol? 
Do not count low-alcohol beer. Put 0 if less than once a month.
Number of times………….
15 b. Approximately how often during the past 12 months have you consumed alcohol?
(Do not count low-alcohol beer)
4-7 times a week   
2-3 times a week      
App. 1 time a week   
2-3 times a month
Appr. 1 time a month  
A few times last year    
Have not drunk alcohol the last year                                        
Have never drunk alcohol
16 a. How many glasses of beer, wine or spirits 
do you usually drink during a two-weeks period? 
Do not count low-alcohol beer. Put 0 if you do not drink alcohol.
Beer…..glasses   Wine…..glasses   Spirits…..glasses
For those who  have consumed alcohol during the  past year
16 b. When you drank alcohol, how many glasses
 did you usually drink ?
Number of glasses………….
16 c. Approximately how often during the past 12 months have you consumed alcohol 
corresponding to at least 5 glasses of spirits in 24 hours?
Number of times………..
16 d. When you drink alcohol, do you usually drink: (Tick one or more).
Beer                  Wine                     Spirits (hard liquor)




18 a. What is the highest level of education you have completed?
Less than 7 year of primary school
 7-10 years primary/secondary school
Technical school, middle school, vocational school, 1-2 years senior high school
High school diploma (3-4 years)
College/university, less than 4 years
College/university, 4 or more years
18 b. How many years education have you completed all together?
(Count every year you went to school)
Number of years………….
ILLNESS IN THE FAMILY
19. Have one or more of your parents or siblings had a heart attack




20. Tick for those relatives who have or have had:








Age when diabetes was first diagnosed
RESIDENLY
21. In which muncipality did you live at the age of 1 year? 
If you did not live in Norway, give country of residence instead of municipality.
………………………..






23. How large is your home?
………m2
24. Do you have wall-to-wall carpets in the living-room?
Yes          No
25. Is there a cat in your home?
Yes           No
FAMILY AND FRIENDS
26 a. With whom do you live? Tick one for each question and  write the number
                                                       Yes                  No                  Number
Spouse/Partner
Other persons older than 18 years 
Persons younger than 18 years 




                                                     Yes            No              Number
Spouse/Partner
Other persons older than 18 years
Persons younger than 18 years 
26 c (only at the questionary for the elderly) 
Where do you live ? Please tick
Home
Institution
Do you live with? 
                                   Yes            No
Spouse/Partner?
Other persones? 
27. How many of the children attend day care/kindergarten/nursery school?
………..
28. How many good friends do you have with whom you can talk confidentially
and who can provide help if you need it?
 (Do not count people you live with, but do include other relatives)
…………………….




30. How often do you usually take part in organised activities, e.g. 
sewing circles, sports clubs, political meetings, religious or other organizations?
Never, or just a few times a year
1-2 times a month (before year 1996), 1-3 times a month (after year 1996)
Approximately once a week
More than once a week
WORK
31. What is your current work situation?
Paid work
Full-time housework
Under education, military service
Unemployed, on leave without payment
32 a. How many hours of paid work do you have per week?
……………….number of hours
32 b. What is your current work situation – paid work?
Yes, full-time
Yes, part time 
No








34. Do you work shifts or nights?
Yes
 No
35. If you have paid or unpaid work, which statement describes your work best?
Mostly sedentary work? 
(e.g. office work, mounting)
Work that requires a lot of walking?
 (e.g. shop assistant, light industrial work, teaching)
Work that requires a lot of walking and lifting?
 (e.g. postman, nursing, construction)
Heavy manual labour? (e.g. forestry, heavy farmwork, heavy construction )




Yes, my own decision
37 a. Do you have any of the following occupations ? 
(full time or part time) Tick one for each question




37 b. What occupation/title did you have at this work? 
(the question refers to another question (not CONOR) about the occupation 
where they worked the longest period during the past year) 
Ex secretary, teacher, industrial worker, nursing, carpenter, l
eader, salesman, driver etc)
Occupation:………………………………………………
YOUR OWN ILLNESS and INJURIES
38. Have you ever had: 
Tick one for each question. State age at event. 
If it has happened several times, write age at the last event.






39. Do you have or have you ever had?
Tick yes or no for each question





Psychological problems for which you have sought help
40. Do you cough almost daily for some periods of the year?
Yes      No 
41. If yes, 
do you bring up phlegm?
Yes       No
42. If you cough almost daily for some periods of the year, have you had this 
kind of cough for as long as 3 months in each of the last two years?
Yes     No
43. How often do you suffer from sleeplessness?
Never, or just a few times a year
1-2 times a month (before year 2000), 1-3 times a month (after year 2000)
Approximately once a week
More than once a week
44. Have you in the last twelve months suffered from sleeplessness  
to the extent that it has affected your ability to work ?             Yes         No                                                                          
USE OF MEDICATION
45. Do you take? 
   Currently             Previously               Never
Lipid lowering drugs
Medications for high blood pressure
46 a. Have you for any length of time in the past year used any of the following
 medications every day or almost daily? 
Indicate how many months you have used the medication. Write 0 if you did not take the medication.
Medications:      
Painkillers             ………months.
Sleeping pills         ………months.
Tranquilizers        ………months.
Antidepressants    ………months.
Allergy pills          ………months.
Asthma medication ………months.
Only medication bought at pharmacy .
Do not include dietary supplements
 
46 b. How often during the last 4 weeks
 have you taken any of the following medication?
Tick one per line
                                                   Daily       Weekly                   Less than            Not taken






Other medication on prescription
46.c Fill in name of medication, reason for use and time used from q 46.b
Brand name           Reason for use                     For how long








47 a. Have you for any length of time in the past year taken any of the 
following daily or almost daily?
Indicate how many months you have used them. Write 0 if you did not take any.
Iron tablets                                         ………..months
Vitamin D supplements                       ………..months
Other vitamin supplements                 ………..months
Cod liver oil                                         ………..months                
47 b. Do you take any of the following?
                                        Yes, daily       Sometimes           No
Cod liver oil, capsules 
Fish oil capsules  
Vitamin and or 
mineral supplements
THE REST OF THE FORM SHOULD ONLY BE FILLED IN BY WOMEN
48. How old were you when you started menstruating?
………..year
49. If you no longer menstruate, how old were you when you stopped menstruating?
………..year
50. Are you pregnant at the moment?
Yes               No                      Unsure                     Postmenopausal
51. How many children have you given birth to?
………children
52. If you have given birth, what year was the child born and how many 
months did you breastfeed each child







53. Do you use or have you ever used:
                                                                Now         Previously        Never
Contraceptive pills (OC) (incl. minipill)
Contraceptive injections
Hormonal intrauterine device
Estrogen (tablets or patches)
Estrogen (cream or suppositories)
54. If you use contraceptive pills, hormonal intrauterine device, or estrogen, 
what brand do you currently use?
………………………………………………



















NORWEGIAN HELATH STUDIES 
Randi Selmer 30 Nov 2007. Updated 23 June 2008. 
Measurements in Health Surveys  1972-2003. 
 
Blood pressure 
1. 1972-84:  Systolic and diastolic blood pressure were measured twice with a standard 
mercury sphygmomanometer after 4 minutes rest. The second measurement has 
usually been used in follow up studies. The interval between first and second 
measurement was 1 minute. Diastolic blood pressure was recorded at the 
disappearance of the Korotkoff sounds (phase V). When phase V was absent, phase IV 
was used. Standard size cuffs were used throughout.  The blood pressure was 
measured on the right upper arm with the person sitting on a chair.    
2. 1985-2003: Pulse recordings, systolic and diastolic blood pressures were measured by 
an automatic device (DINAMAP, Criticon, Tampa, USA), which measured the blood 
pressure in mm Hg automatically by an oscillometric method. After 2 minutes 
preceding rest, three recordings were made at one-minute intervals. The values of the 
mean of the second and third systolic blood pressure measurements were used in 
calculating the cardiovascular risk score (CVD risk score). Arm circumference of right 
upper arm was measured 10 cm above fossa cubiti. From these measurements small, 
medium or large cuff was chosen. The blood pressure was measured on the right upper 
arm with the person sitting on a chair.    
The two methods have been compared  (PG Lund-Larsen: Blodtrykk målt med 
kvikksølvmanometer og med Dinamap under feltforhold- en sammenligning. Norsk 
epidemiologi 1997; 7 (2): 235-41)  
 
Serum analyses 
Sera from the screenings were sent to the Department of Clinical Chemistry, Ullevål 
University Hospital, Oslo, Norway 
 
Serum lipids 
Non-enzymatic methods: Total cholesterol and triglycerides 
Non enzymatic methods were used in Oslo 1972-73, first screening in Finnmark, Oppland and 
Sogn og Fjordane 1974-78 and second screening in Finnmark 1977-78. Enzymatic methods 
were used from second screening in Sogn og Fjordane 1980. 
 
Stensvold et al. BMJ 1993: 
 “A blood sample was taken from  non-fasting subjects and analysed for serum concentrations 
of total cholesterol and triglycerides, both components being measured non-enzymatically on 
a Tchnicon AutoAnalyzer. On later comparison with enzymatic methods, the non-enzymatic 
methods used gave on average 10% higher triglyceride values and 8% higher cholesterol 
values. The participants reported the time  since last meal.”  
 
The triglyceride values included in the data set are corrected values compatible with 
enzymatic methods according to the formula: 
 (New method) = 0.90 x (Old method) - 0.11 
 
The cholesterol values included in the data set are corrected values compatible with enzymatic 
methods according to the formula: 
 (New method) = 0.92 x (Old method) + 0.03 
 
The formula was evolved after extensive test program comparing new and old method. 
 
Enzymatic methods: 
All measurements of HDL cholesterol were enzymatic. (Stensvold I, Urdal P, Thürmer H, 
Tverdal A, Lund-Larsen PG, Foss OP. High-density lipoprotein cholesterol and coronary, 
cardiovascular and all cause mortality among middle-aged Norwegian men and women.Eur 
Heart J. 1992 Sep;13(9):1155-63.)    
   
Non-fasting serum total cholesterol, serum HDL cholesterol, glucose and serum triglycerides 
were measured directly by an enzymatic method (Technicon or Hitachi autoanalyzer). 
Seronorm Lipoprotein was used as internal quality control material for the lipid analyses and 
Autonorm Human Liquid for the glucose. The control material was done at the start and for 
every 30th sample.  
 
Stability of cholesterol measurements from 1972 has been documented ( OP Foss and P 
Urdal: Kolesterol gjennom mer enn 25 år: kan svarene sammenliknes over så lang tid?  Norsk 
epidemiologi 2003; 13 (1): 85-88) ) 
 
Glucose 
Serum glucose was measured in first screening in Finnmark, Oppland and Sogn og Fjordane 
1974-78 and second screening in Finnmark 1977-78 and in a sample in second screening in 
Oppland 1981-83 by a non enzymatic method by Brown ( ME Brown: Ultra-micro sugar 
determinations using 2, 9-dimethyl-1, 10-phenanthroline hydrochloride (Neocuproine). 
Diebetes 10:60, 1961.) The same method was used in  Oslo 1972-73. The results obtained 
with this method were about 0.8-1.1 mmol/l higher than the true concentration defined as the 
value found with a specific enzymatic method.  
    
From 1994 non fasting serum glucose was measured by enzymatic method described above.  
The old glucose values have not been adjusted to levels comparable with enzymatic methods.   
 
Weight and height 
Body weight (in kilograms, one decimal) and height (in centimetres, one decimal) was 
measured according to standard protocol with the participants wearing light clothing without 
shoes (manually recorded until 2000 and after that with an electronic Height and Weight 
scale)  
 
Waist and hip 
Waist and hip were measured from Finnmark and Akershus 1996/97 and onwards. Waist 
circumference was measured at the umbilicus to the nearest cm with the subject standing and 
breathing normally. In obese individuals, waist circumference was defined as the midpoint 
between the iliac crest and lower margin of ribs. Hip circumference was measured as the 
maximum circumference around the buttocks. Both waist and hip were measured with a 
measuring tape of steel – which was emphasized to be horizontal. Waist and hip 
circumference were used to calculate the waist-hip ratio using the formula waist (cm)/ hip 
circumference (cm).  
 
 
Measurements of lipids in three counties 1974-1988 
 Finnmark Sogn og Fjordane Oppland 
Name    





mg/dl old method 
 
total cholesterol mg/dl 
old method 
 
total cholesterol mg/dl 
old method 
 
u1kolest total cholesterol old 
method converted to 
mmol/l by factor 
0.02586 
total cholesterol old 
method converted to 
mmol/l by factor 
0.02586 
total cholesterol old 
method converted to 
mmol/l by factor 
0.02586 
 
u1kolenz total cholesterol mmol/l converted to 
enzymatic values 
from u1kolest by 
formulae 
total cholesterol 
mmol/l converted to 
enzymatic values 
from u1kolest by 
formulae 
 
total cholesterol mmol/l 
converted to enzymatic 
values from u1kolest by 
formulae 
 
No HDL measurements 
 




triglycerides mmol/l old 
method 
 
u1trienz triglycerides mmol/l converted to 
enzymatic values 









converted to enzymatic 
values from u1trigly by 
formulae 




mg/dl old method 
total cholesterol mg/dl 
enzymatic method 
total cholesterol mg/dl 
enzymatic method 
 
u2kolest total cholesterol old 
method converted to 




converted to mmol/l 
by factor 0.02586 
total cholesterol 
enzymatic method 
converted to mmol/l by 
factor 0.02586 
 
u2kolenz total cholesterol mmol/l converted to 
enzymatic values 






u2hdlkol mg/dl, enzymatic* mg/dl, enzymatic* mg/dl, enzymatic* 
 
u2hdlkl 
converted to mmol/l 
by factor 0.02586 
converted to mmol/l 
by factor 0.02586 











u2trienz triglycerides mmol/l converted to 
enzymatic values 






Screening 3    
 
u3kolest/u3kolenz 
All values enzymatic mmol/l . Sometimes renamed u3kolest to 





All values enzymatic 
mmol/l* 




All values enzymatic mmol/l . Sometimes renamed u3trigly to u3trienz 
to indicate that these are enzymatic values. 
   
*Eur Heart J. 1992 Sep; 13(9):1155-63. 
High-density lipoprotein cholesterol and coronary, cardiovascular and all-cause mortality among middle-




SUMMARY THREE COUNTIES STUDY 
The cardiovascular surveys in Finnmark, Sogn og Fjordane and Oppland 1974-78,  
1977-83 and 1985-88. Sources: Final reports from each survey in each county 
 




% attendance,  
fully invited 
ages  
Finnmark 1974-75 All residents in age 35-49 by Dec 1974 
(born 25-39). Age 20-34: 10% random 
samples 
17401 14340 82.4  
Men: 78.8, 
women: 86.2 
 1977-78 All residents born 1925-42, samples in 
younger ages from 20 years. 
20647 17145 83.0 
Men: 79.2 
women: 87.3 
 1987-88 All residents in age 40-62 by Dec 1987 
(born 1925-47) + those aged 30-39 and 
invited in 1977-78 + 10 % of non-invited 
in age 20-39. All residents 18 years or 
older in Bugøynes.  





1975-76 All residents in age 35-49 by Dec 1975 
(born 1926-40) + 10 % random sample in 
age 20-39. 
16603 14966 90.1  
Men: 87.4, 
women:93.1 
 1980-81 All residents born 1926-40 + samples in 
younger ages from 17 years. 
19506 17473 89.6  
Men: 86.8, 
women:92.6 
 1985-86 All residents in age 40-54 by Dec 31 1985 
(born 1931-45) + those younger than 40 
years and invited in 1980-81  + 5-% 
sample of those in age 20-39 not invited in 
1980-81 +10 % sample of invited in 1980-
81 in age 55-59. A few older subjects in a 
hypertension register. 
21423 18669 87.1 
Men: 83.9, 
women: 90.7 
Oppland 1976-78 All in age 35-49 by Dec 1976 (born 1927-
41) +10- % random sample in age 20-39. 
31620 28399 89.8  
Men: 87.8, 
women: 91.8 
 1981-83 All residents born 1927-41 + samples in 
younger ages from 20 years. 
31581 28437 90.0  
Men: 88.1, 
women: 91.9 
 1986-88 All residents aged 40-54 on Dec 1986 
(born 1932-46) + all residents below 
40 years and a 10 % sample in age 55-
59 if invited in 1981-83 + 5-% of not 
invited in 1981-83 in age 20-39. A few 
older subjects in a hypertension 
register.  









MATERIALS AND METHODS  
DESCPRIPTION 
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Cohort Norway (CONOR): Materials and methods 
Anne Johanne Søgaard, Norwegian Institute of Public Health, April 2006 
CONOR (COhort NORway) is a large collaborative project between 
epidemiological centres at the University of Tromsø, the Norwegian University of 
Science and Technology in Trondheim, the University of Bergen, the University 
of Oslo, and the Norwegian Institute of Public Health. 
 
Data from 10 regional studies 
In CONOR, regional data from 10 different epidemiological studies have been 
merged into a national database, which is more representative of the Norwegian 
population than each of the individual sites.  
 
The database consists of information obtained from questionnaires, a simple physical 
examination, analyses of blood samples, and frozen stored blood and/or DNA. The 
main purpose of CONOR is to study the aetiology of rare diseases by testing 
environmental, inheritable, cultural and social factors in order to describe the 
dispersion of diseases and risk factors by time, place and socio-demographic factors.  
 
CONOR is particularly suitable for studying gene-environment interactions and for 
linkages to various national registers (eg. cancer-, cause of death-, hospital- and 
medical birth registers). 
 
Invitation and procedures 
Altogether 309,832 individuals were invited in the 10 studies based on addresses from 
the Population registry of Norway (Hammer, 2002). Some of the individual studies 
invited all subjects above a specific age (for example all above 19 years in HUNT II), 
whereas others invited all subjects in selected age groups (for example all 30-, 40-, 
45-, 60 and 75 years in OPPHED and TROFINN). The web site for each study 
contains more detailed information (see Table 1).  
 
In all CONOR surveys, the data collection followed a standard procedure. Letters of 
invitation were mailed about 2 weeks before the time of appointment and included a 
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questionnaire and a booklet with the aims of the study and information about the 
examinations and procedures. At the screening, the main questionnaire was collected 
from the attendees, they went through a physical examination and a non-fasting blood 
sample was drawn for analyses in fresh serum. Another sample was stored at minus 
80 degrees. In most studies, the participants were given one or two supplementary 
questionnaires, which they were instructed to fill in at home and to return by mail in 
pre-addressed envelopes.  
 
About four weeks after attending the examination, a letter with some results from the 
examination and blood tests was sent to all participants. Those with the highest scores 
of cardiovascular risk were offered a new clinical examination at the regional 




All surveys have been carried out in collaboration with the National Health Screening 
Service, Oslo (now Norwegian Institute of Public Health). Experienced and trained 
personnel conducted all procedures. Non-fasting serum total and HDL cholesterol, 
glucose and triglycerides were measured directly by an enzymatic method 
(Boehringer 148393, Boehringer-Mannheim, Federal Republic of Germany – from 
2000 Hitachi 917 auto analyzer, Roche Diagnostic, Switzerland).  
 
The Department of Clinical Chemistry, Ullevål University Hospital, Oslo, performed 
all laboratory assessments except for HUNT II where the analyses were performed at 
the Department of Clinical Chemistry, Innherad Hospital, Levanger. Comparisons of 
blood-samples were performed between the laboratories, and small differences were 
found (Tverdal A et al 1997). Calibration procedures were carried out between these 
laboratories in connection with the surveys (Dr. Lund-Larsen PG, National Health 
Screening Service, personal communication). An acceptable stability of the laboratory 
analyses over time in the population surveys has been reported (Foss & Urdal, 2003). 
 
Heart rate, systolic and diastolic blood pressures were measured by an automatic 
device (DINAMAP, Criticon, Tampa, USA), which measured the blood pressure in 
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mm Hg automatically by an oscillometric method. After 2 minutes of preceding rest, 
three recordings were made at one-minute intervals. Mean values of the second and 
third systolic blood pressure measurements were used in calculating the 
cardiovascular risk score (CVD risk score) (Tverdal et al., 1989). The stability of the 
blood-pressure measures have been evaluated and deemed acceptable (Lund-Larsen, 
1997). 
 
Body weight (in kilograms, one decimal) and height (in cm, one decimal) was 
measured according to a standard protocol with the participants wearing light clothing 
without shoes (manually recorded until 2000 and after that with an electronic Height 
and Weight Scale). Body mass index (BMI) was calculated as kg/m2. Waist 
circumference was measured at the umbilicus to the nearest cm and with the subject 
standing and breathing normally. In obese individuals, waist circumference was 
defined as the midpoint between the iliac crest and lower margin of ribs. Hip 
circumference was measured as the maximum circumference around the buttocks. 
Both waist and hip were measured with a measuring tape of steel – which was 
emphasized to be horizontal. Waist and hip circumference were used to calculate the 
waist-hip ratio using the formula waist (cm)/ hip circumference (cm). 
 
Most of the studies consist of a central core and several supplementary projects – for 
example extra samples of blood, ECG, ultrasonographic examination of carotid artery 
and abdominal aorta, and bone mineral densitometry (BMD). The web site for each 
study contains more detailed information (see Table 1). Only a limited and mutual 
core of each study constitutes CONOR. Most of the studies have published reference 
papers with more detailed information about their own study (Table 2). 
 
The CONOR-questions 
All surveys used 50 common CONOR-questions agreed upon before the first CONOR 
survey in Tromsø in 1994. The exact wording of the questions is available at the 
CONOR web site (http://www.fhi.no/dav/CA11310499.doc). Some of these 
questions were placed on the second questionnaire handed out at the screening station 
– and thus have lower response rate.  
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The CONOR-questions cover the following main topics: Self-reported health and 
diseases such as diabetes, asthma, coronary heart disease, stroke and mental distress, 
musculo-skeletal pains, family history of disease, risk factors and lifestyle, 
environment while growing up, social network and social support, education, work 
and housing, some types of occupation, use of medications and reproductive history 
(women).  
 
Several of these questions have been evaluated or validated previously and were 
deemed acceptable (Tretli et al., 1982; Jacobsen & Thelle, 1987; Løchen & 
Rasmussen, 1992; Thune et al., 1997, Joakimsen et al., 1998; Saltin & Grimsby, 1968; 
Derogatis et al., 1974; Ainsworth et al., 1996; Brugha et al., 1985; Strand et al., 2003; 
Søgaard et al 2003). The Population registry of Norway, which was used for 
invitation, contains information about gender, birth date, marital status, address and 
country of birth.  
 
Participation in the CONOR studies 
Altogether 181,891 subjects accepted to participate and provided a declaration of 
consent – 7,460 of these participated in more than one survey. The age distributing of 
these 174 430 participants is shown in table 3. The participation rate varied among the 
surveys. The participation was slightly reduced throughout the study-period 1994-
2003 - and was higher in rural as compared to urban areas.  
   
Ethics and approvals 
All participants of the studies included in CONOR, have given their written consent. 
The participant’s names and personal ID numbers are omitted when data are used for 
research purposes. The Norwegian Data Inspectorate has approved - and the Regional 
Committees for Medical Research Ethics has evaluated each individual study. The 
studies have been conducted in full accordance with the World Medical Association 
Declaration of Helsinki.  
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TABLE 1. Number of invited and participating subjects in Cohort Norway (CONOR) 1994-2003. 
    Number of participants * 
 






groups in years‡ 
Men Women Total Web address 
Tromsø IV (The fourth Tromsø Study) 1994-1995 37,558 25 + 12,797 14,128 26,925 http://uit.no/tromsoundersokels
en/tromso4/2 
HUNT II (The second North-Trøndelag Health Study) 1995-1997 94,196 20 + 30,442 34,576 65,018 http://www.hunt.ntnu.no/ 
HUSK (The Hordaland Health Study) 1997-1999 38,587 40-44, 46-47, 70-
72 
11,678 13,852 25,530 http://www.uib.no/isf/husk/ 
Oslo II (The second Oslo Study)  2000 14,209§ 48-77 6,919  6,919 http://www.fhi.no/artikler/?id=54
685 
HUBRO (The Oslo Health Study)  2000-2001 58,660# 30, 31, 40, 45, 
46, 59/ 60,  
75/ 76 
9,751 12,264 22,015 http://www.fhi.no/artikler/?id=5
4464 
OPPHED (The Oppland and Hedmark Health Study) 2000-2001 22,327 30, 40, 45, 60, 75 5,650 6,752 12,402 http://www.fhi.no/artikler/?id=2
8233 
Tromsø V (The fifth Tromsø Study) 2001 10,353 30 + 3,491 4,586 8,077** http://uit.no/tromsoundersokels
en/tromso5/2  
I-HUBRO (The Oslo Immigrant Health  Study) 2002 12,088†† 20-60 1,915 1,768 3,683 http://www.fhi.no/artikler/?id=2
8217 
TROFINN (The Troms and Finnmark Health Study) ‡‡ 2002 16,229 30-77 4,318 5,009 9,327 http://www.fhi.no/artikler/?id=2
8261 
MoRo II (The second part of the Romsås in Motion Study) 2003 5,535 34-70    899 1,096 1,995 http://www.fhi.no/artikler/?id=2
8254 
 

















*  Number of participants equals those who attended the survey and/or answered at least one questionnaire and signed a written consent. 7,460 persons participated in a second 
CONOR survey and 1 person participated in a third. Thus, the total numbers of participants with consent were 174,430. 
†  The numbers include all individuals invited. The individual surveys could have published papers with slightly different total numbers.  
‡  HUSK: All 40-44 years and those participating in a study in 1992-93 born 1950-51 and 1925-27; Oslo II: All those invited to the Oslo Study 1972-73, except those invited to 
HUBRO and MoRo I (Invited in 1972/73: all men born 1923-32 and 7% random sample of those born 1933-52); Tromsø V: All 30, 40, 45, 60, 75 years and all those participating in 
phase II in Tromsø IV - which included: all born 1920-1939, 5-10% sample of other age groups attending phase I, all women born 1940-44; I-HUBRO: 30% random sample of people 
born in Pakistan, all born in Turkey, Sri Lanka, Iran, Vietnam - except those invited to HUBRO;  MoRo II: All those participating in a study in 2 local districts in Oslo in 2000 (MoRo 
October 2007 8 
I) born 1933-1969 – except those participating in HUBRO; TROFINN: All 30, 40, 45, 60, 75 years and all those participating in three Finnmark studies in the period 1974-1988 – 
which included: All born 1925-1947, all born 1948-1968 invited to Finnmark I, II or III.  
§  2,515 more men who belonged to the Oslo II cohort, also belonged to the HUBRO cohort, and were only invited to HUBRO. Of these 1,320 men participated. They are only 
counted as invited to HUBRO. 50 more men belonged to the MoRo-cohort, and are only counted as invited there. 
#  Include 17,308 invitees (31 and 46 years – additional cohorts) who were not reminded. The attendance-rate of these was low.  
** 7,166 of these participated also in Tromsø IV. 
†† Include 4,116 persons (20-30 years – additional cohort) who were not reminded. The attendance-rate of these was very low. 
‡‡ Include 18 of 25 municipalities in Troms and 10 of 19 municipalities in Finnmark. The other municipalities participated in Tromsø V and in SAMINOR, i.e. a health survey in 






Table 2. Reference papers to the 10 participating CONOR studies. 
 
Tromsø IV: Wilsgard T. Longitudinal analyses of cardiovascular risk factors. The Tromsø study 1974-1995. ISM skriftserie nr. 65. Tromsø, 
Norway: Institute of Community Medicine, University of Tromsø, 2002. 
HUNT II: Holmen J, Midthjell K, Krüger Ø, Langhammer A, Lingaas Holmen T, Bratberg GH, Vatten L, Lund-Larsen PG. The Nord-Trøndelag 
Health Study 1995-97 (HUNT 2): Objectives, contents, methods and participation. Nor J Epidemiol 2003; 13: 19-32. 
HUSK: Bjelland I, Tell GS, Vollset SE, Refsum H, Ueland PM. Folate, vitamin B12, homocysteine, and the MTHFR 677C->T polymorphism in 
anxiety and depression: the Hordaland Homocysteine Study. Arch Gen Psychiatry 2003 Jun;60(6):618-26 - and 
Sanne B, Mykletun A, Dahl AA, Moen BE, Tell GS; Hordaland Health Study. Occupational differences in levels of anxiety and depression: the 
Hordaland Health Study. J Occup Environ Med 2003;45:628-38. 
Oslo II: Lund  Håheim L, Holme I, Hjermann I, Søgaard AJ, Lund-Larsen PG, Leren P. Resultater fra Oslo-undersøkelser blant de samme menn i 
1972/3 og i år 2000. Endring i risikofaktorer for hjerte- og karsykdom. Tidskr Nor Laegefor (Cond accepted)  
HUBRO: Søgaard AJ, Selmer R, Bjertness E, Thelle D. The Oslo Health Study. The impact of self-selection in a large, population-based survey. Int 
J Equity Health 2004:3: 1-24. Online: http://www.equityhealthj.com/content/3/1/3 
OPPHED: Only web-site - http://www.fhi.no/artikler/?id=28233 
Tromsø V: Johnsen SH, Fosse E, Joakimsen O, Mathiesen EB, Stensland-Bugge E, Njølstad I, Arnesen E. Monocyte count is a predictor of novel 
plaque formation: a 7-year follow-up study of 2610 persons without carotid plaque at baseline the Tromso Study. Stroke. 2005;36(4):715-9.  
I-HUBRO: Holvik K, Meyer HE, Haug E, Brunvand L.Prevalence and predictors of vitamin D deficiency in five immigrant groups living in Oslo, 
Norway: the Oslo Immigrant Health Study. Eur J Clin Nutr. 2005;59:57-63. 
TROFINN: Only web-site - http://www.fhi.no/artikler/?id=28260 
07.07.06 
MoRo II: Jenum AK,. Anderssen SA, Birkeland KI, Holme I, Graff-Iversen S, Lorentzen C, Ommundsen Y, Raastad T, Ødegaard AK, Bahr R. Promoting 
physical activity in a low-income multi-ethnic district: behavioural, psychological and biological effects of a pseudo-experimental community 
intervention study to reduce risk factors for diabetes and cardiovascular disease (submitted) 
CONOR: Engeland A, Søgaard AJ. CONOR (Cohort NORway) – en oversikt over en unik forskningsdatabank. Nor J Epidemiol 2003;13:73-7 - and 





Table 3 Number of participants in Cohort Norway (1994-2003)  
according to gender and age-groups (at the time they attended 
the screening station). If participating in more than one study,  
only the last one is counted. 
 
 Men  Women  Total 
Age N  N  N 
<20 116  148  264 
20-29 5 884  7 236  13 120 
30-39 13 322  15 547  28 869 
40-49 27 969  32 148  60 117 
50-59 10 517  10 176  20 693 
60-69 12 229  10 373  22 602 
70-79 13 119  11 883  25 002 
80+ 1 460  2 303  3 763 
Total 84 616  89 814  174 430 
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How did the study come about?
A number of large population-based cardiovascular surveys
have been conducted in Norway since the beginning of the
1970s. The surveys were carried out by the National Health
Screening Service in cooperation with the universities and local
health authorities. All surveys comprised a common set of
questions, standardized anthropometric and blood pressure
measurements and non-fasting blood samples that were
analysed for serum lipids at the Ullevål Hospital Laboratory.
These surveys provided considerable experience in conducting
large-scale population-based surveys, thus an important back-
ground for the Cohort of Norway (CONOR). In the late 1980s
the Research Council of Norway established a programme in
epidemiology. This also gave stimulus to the idea of establish-
ing a cohort including both core survey data and stored blood
samples. In the early 1990s, all universities, the National Health
Screening Service, The National Institute of Public Health and
the Cancer Registry discussed the possibility of a national
representative cohort.1 The issue of storing blood samples for
future analyses raised some concern and it was discussed in the
parliament. In 1994, the Ministry of Health appointed the
Steering Committee for the CONOR collaboration. In 1994–95,
the fourth round of the Tromsø Study was conducted, and
became the first survey to provide data and blood samples for
CONOR. During the years 1994–2003, a number of health
surveys that were carried out in other counties and cities also
provided similar data for the network. So far, 10 different
surveys have provided data and blood samples for CONOR
(Figure 1). The administrative responsibility for CONOR was
given to the Norwegian Institute of Public Health (NIPH) in
2002. The CONOR collaboration is currently a research
collaboration between the NIPH and the Universities of
Bergen, Oslo, Tromsø and Trondheim.
The purpose of CONOR
The CONOR cohort has not been established on the basis of any
single hypothesis but is rather a multipurpose study. The
ambition was to set up a sufficiently large enough cohort to
study aetiological factors for a wide range of diseases.
Additionally, this cohort should make it possible to describe
Norwegian men and women in terms of distribution of
exposures and health status according to time, place and
socio-economic factors.
In 2002, CONOR and the Norwegian Mother and Child study
(MoBa),2 received a 5-year grant from the Norwegian Research
Council to build a technology platform under the Functional
Genomics programme (FUGE), called the Biobanks for Health
in Norway (Biohealth) platform.3 The overall aim was to
investigate separate and combined effects of genes and
environment on the risk of disease.
Who is in the sample?
Altogether 309 742 individuals were invited to the 10 surveys
based on the 11-digit personal identifier and addresses from the
Population Registry of Norway.4 The goal is to include 200 000
participants. We defined those who attended the survey and/or
answered at least one questionnaire and signed a written
informed consent as participants. The numbers in Table 1
include individuals who participated and had given their
written consent for research and linkage to health registries.
A total of 7309 persons participated in two CONOR surveys, and
one person participated in three. Thus, the total number of
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individuals in the CONOR cohort is 173 236. The distribution of
age at the first examination and the number of deaths during
follow-up through 2003 is given in Table 2. The individual
surveys may have published papers with slightly different total
numbers. Sampling procedures differed somewhat between the
individual studies. The web site for each study contains more
detailed information (Table 1).
What has been measured?
In all the CONOR surveys, the data collection followed
a standard procedure. Letters of invitation were mailed about
2 weeks before the time of appointment and included a
questionnaire and a brochure with the aims of the study and
information about the examinations and procedures. At the
screening, this initial questionnaire was collected from the
attendees, participants underwent a physical examination and
a non-fasting blood sample was drawn. In most studies, the
participants were given one or two supplementary question-
naires, which they were instructed to fill in at home and return
by mail in pre-addressed stamped envelopes.
About 4 weeks after attending the examination, a letter with
selected results from the examination and blood tests was sent
to all participants. Those with the highest scores of cardiovas-
cular risk (a modified Framingham risk score based on
multiplying the relative risks attributable to the subject’s
gender, serum cholesterol, systolic blood pressure the number
of cigarettes currently smoked per day and family history of
Table 1 Number of invited and participating subjects in cohort of Norway (CONOR) 1994–2003









Men Women Total Web address
Tromsø IV (The fourth Tromsø
Study)
1994–1995 37 558 25þ 12 797 14 128 26 925 http://uit.no/tromsoundersokelsen/tromso4/2
HUNT II (The second
North-Trøndelag Study)
1995–1997 94 196 20þ 30 441 34 576 65 017 http://www.hunt.ntnu.no/
HUSK (The Hordaland Health
Study)
1997–1999 38 587 40–44, 46–47,
70–72
11 678 13 851 25 529 http://www.uib.no/isf/husk/
Oslo II (The second Oslo Study) 2000 14 209 48–77 6919 6919 http://www.fhi.no/artikler/?id¼54685
HUBRO (The Oslo Health Study) 2000–2001 58 660 30, 31, 40, 45,
46, 59/60,
75/76
9509 11 852 21 361 http://www.fhi.no/artikler/?id¼54464
OPPHED (The Oppland and
Hedmark Health Study)
2000–2001 22 327 30, 40, 45,
60, 75
5602 6661 12 263 http://www.fhi.no/artikler/?id¼28233
Tromsø V (The fifth Tromsø
Study)
2001 10 353 30þ 3440 4457 7897 http://uit.no/tromsoundersokelsen/tromso5/2
I-HUBRO (The Oslo Immigrant
Health Study)
2002 12 088 20–60 1877 1737 3614 http://www.fhi.no/artikler/?id¼28217
TROFINN (The Troms and
Finnmark Health Study)
2002 16 229 30–77 4196 4836 9032 http://www.fhi.no/artikler/?id¼28261
MoRo II (The second part of
the Romsås in Motion Study)
2003 5535 34–70 896 1093 1989 http://www.fhi.no/artikler/?id¼28254
CONOR (Cohort Norway)a 1994–2003 309 742 20–103
Sum of participants 87 355 93 191 180 546 http://www.fhi.no/artikler/?id¼28138
Sum of individuals 84 153 89 083 173 236
aNumber of participants equals those who attended the survey and agreed that information from the CONOR survey and blood samples can be
linked to other registers and used in research. A total of 7310 individuals participated in more than one survey. Thus, the total number of individuals
equals 173 236.
Figure 1 Map of Norwegian counties with location of each sub-study
included in cohort of Norway (CONOR)
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coronary heart disease) were advised to visit their own general
practitioner, and in some cases offered a follow-up examination
at the local hospital.5
Measures
Only a restricted core set of measurements and questionnaire
responses constitute the CONOR data. Most individual studies
that contribute to CONOR have more detailed measurements and
questionnaire data. In the following section we describe the key
core measurements that all studies contribute to CONOR; at the
end we briefly describe some of the additional measurements
that are in some of the contributing individual studies. All surveys
were carried out in collaboration with the National Health Screen-
ing Service, Oslo (now the NIPH). Experienced and trained
personnel conducted all procedures. Non-fasting serum total-
and HDL-cholesterol, glucose and triglycerides were measured
directly by an enzymatic method (Boehringer 148393, Boehringer-
Mannheim, Federal Republic of Germany—from 2000 Hitachi 917
auto analyzer, Roche Diagnostic, Switzerland).
The Department of Clinical Chemistry, Ullevål University
Hospital, Oslo, performed all laboratory assessments except for
HUNT II (The second North-Trøndelag Study) where the analyses
were performed at the Department of Clinical Chemistry, Levanger
Hospital, Levanger. In Tromsø IV and V, cholesterol and triglycer-
ides were measured at the Department of Clinical Chemistry,
University Hospital North-Norway, Tromsø. Calibration procedures
were carried out between these laboratories in connection with the
surveys (Dr P.G. Lund-Larsen, National Health Screening Service,
personal communication). An acceptable stability of the laboratory
analyses over time in the population surveys has been reported.6
Heart rate, systolic and diastolic blood pressures were mea-
sured by an automatic device (DINAMAP, Criticon, Tampa,
FL,USA). After 2 min of seated resting, three recordings were
made at 1-min intervals. Mean values of the second and third
systolic blood pressure measurements were used in calculating
the cardiovascular risk score (CVD risk score) (Tverdal, 1989
5/id). The stability of the blood pressure measures has been
evaluated and deemed acceptable.7
Body weight (in kilograms, one decimal) and height (in
centimetres, one decimal) was measured according to a standard
protocol with the participants wearing light clothing without
shoes (manually recorded until 2000 and after that with an
electronic Height and Weight Scale). Body mass index (BMI) was
calculated as kilograms per square metre. Waist circumference
was measured at the umbilicus to the nearest centimetre and with
the subject standing and breathing normally. In obese individuals,
waist circumference was defined as the midpoint between the iliac
crest and lower margin of ribs. Hip circumference was measured
as the maximum circumference around the buttocks. Both waist
and hip were measured with a measuring tape of steel—which
was emphasized to be placed horizontally. The waist–hip
circumferences were used to calculate the waist–hip ratio.
Most individual studies that contribute to CONOR have
several additional measurements—for example, extra samples
of blood, ECG and ultrasonographic examination of carotid
artery and abdominal aorta. Four of the study sites measured
bone mineral density (DEXA and/or SXA) and have established
a research group called Norwegian Epidemiologic Osteoporosis
Studies (NOREPOS).8 Altogether, around 28 000 individuals
have had their bone mineral density measured and currently a
number of collaborative studies are carried out.
The CONOR questions
All surveys used about 50 core CONOR questions agreed upon
before the first CONOR survey in Tromsø in 1994. The exact
wording of the questions is available at the CONOR website
(http://www.fhi.no/dav/CA11310499.doc). Some questions have
been slightly modified over the years.
The CONOR questions cover the following main topics: self-
reported health and diseases such as diabetes, asthma, coronary
heart disease, stroke and mental distress, musculo-skeletal
pains, family history of disease, risk factors and lifestyle, social
network and social support, education, work and housing, some
types of occupation, use of medications and reproductive
history (women).
Several of the questions have been evaluated or validated and
deemed acceptable.9–18 The Population Registry of Norway that
was used to identify eligible subjects, contains information about
gender, date of birth, marital status, address and country of birth.
Blood samples
Blood samples were drawn from the CONOR participants. EDTA
blood for CONOR and the other sub-surveys have normally
been collected in 7 or 5 ml vacutainers. These vacutainers were
made by different manufacturers but were normally made of
polypropylene. DNA has been extracted from more than 90 000
specimens to medio 2007, and Biohealth intends to extract
DNA from all samples by Spring 2008. The extracted DNA and
an additional sample of 1.25 ml EDTA-blood will be stored at a
national biobank storage site at HUNT/NTNU biobank in
Levanger (Mid-Norway).
What has been found?
Although a number of analyses from each participating study
have been conducted, the CONOR file has only recently been
compiled and made available for research. The first CONOR
project was anchored in NOREPOS describing urban–rural
differences in forearm fractures.19 Other methodological and
validation studies have been completed as described above.
What are the main strengths and
weaknesses?
The CONOR database has several strengths: it is population
based including populations from various parts of Norway, both
rural and urban. The 11-digit personal identification number
makes it possible to link cohort participants to national health
registries. At present, several large linkages to other registers
have been or are in the process of being conducted. These
include linkages with census-based data for the whole
population and the Medical Birth Registry of Norway,
Disability Registry, Cancer Registry of Norway. Tables 2 and 3
present number of deaths and new cases of cancer in CONOR
since date of examination by linkage to the death and cancer
registries. Other large linkages include data from the
Norwegian Drug Prescription Database and information from
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health surveys in several counties in the 1970s. There are also a
number of disease registers that may be linked to the CONOR
database. Earlier this year, the government passed a new
legislation to make the national hospital discharge register
personal identifiable, which would be possible to link to
CONOR in the near future.
A major strength of CONOR is its sample size that means it
would be able to make a unique contribution to establish main
genetic effects and gene–environmental interactions, since
precise and robust estimation of these effects requires very
large sample sizes.20,21 Our aim is to reach 200 000 individuals
with blood samples and extracted DNA and we anticipate
reaching this sample size by Spring 2008. For some hypotheses,
it would be most efficient to employ a nested case control study
design within CONOR, and we anticipate several such studies
in the future. This comparatively large sample size means cases
for a number of common and less common diseases may be
identified from various sources.
There are some important weaknesses: the overall participa-
tion rate is 58% and is lowest in the surveys in Oslo and other
urban areas and became lower throughout the study period.
However, the overall participation rate is influenced by low
participation rate in those aged 430 years. The study
population is somewhat heterogeneous as it includes sampling
from 10 geographical areas with various age groups included
over a 10-year period. The number of core variables is limited,
and in some cases the wording of questions is slightly changed
over the years.
Can I get hold of the data? Where
can I find out more?
Guidelines have been developed for projects using data from
CONOR (www.fhi.no). These shall ensure that projects will
have a high scientific quality, facilitate quick publication of
results from CONOR and make the data accessible for research.
Research groups may apply for access. A project leader must be
appointed. Researchers not residing in Norway are advised to
seek contact with Norwegian counterparts. The study objectives
should be within the broader aims of CONOR. Further details
of these guidelines are provided at the CONOR website.
Applications and enquiries can be sent electronically to the
Norwegian Public Health Institute (email: conor@fhi.no).
Applications will be evaluated by the CONOR Steering
Committee.
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Inclusions selected on survey from data manager: 
 
3 Counties I 62 220 
3 Counties II 9 188 
3 Counties III 22 538 
CONOR 137 182 
40 Years (total) 403 691 
































Analytical cohort: 602, 242( m=299,376, f=302,866) 
 
Cancer cases in cohort by smoking status 
 
 Never-smokers Former-smokers Current-smokers Total 
Breast cancer 3,028 1,581 2,881 7,490* 
Colon cancer 1,368 1,099 1,531 3,998 
Rectal cancer| 648 602 926 2,176 
 





Cancer Mortality in cohort by smoking  
 
 
 Never-smokers Former-smokers Current-smokers Total 
Breast cancer 459 216 431 1,106* 
Colon cancer 1,607 443 642 1,607 
Rectal cancer| 202 181 343 726 
 










The daily-smokers variable in CONOR was based on question “Do you smoke daily?” (In 
CONOR, this question includes cigarettes, pipe and cigar daily smokers, according to 
CONOR documentation (variable a8_0)). 
 
In Oslo health study I, the question “Do you smoke daily?” is used for current smokers. 





In the Norwegian counties study (I, II and III), this was based on the question “Do you smoke 
daily now?” A positive answer will give a categorization of daily smoker. (We do not 
consider other answers regarding smoking to classify the current smokers.)  
 
40 years I was based on the question “Do you smoke daily now?” Answering “Yes” will be 
current smokers.  
 
40 years II was based on the questions “Do you smoke cigarettes daily? Or “Do you smoke 
cigar daily?” “Do you smoke pipe daily?” answering “Yes” to any of these questions gives 
daily-smokers. 
 
The 40 years III and IV was based on “Do you smoke cigarettes daily?” or “Do you smoke 
cigar daily?” or “Do you smoke pipe daily?” If participants have answered “Yes” on any of 







After we got all current smokers, then we categorized remaining participants in the former-
smokers category as below: 
In CONOR if participants have valid answer (greater than 0) in questions “How long time 
since quit smoking (a_9)?” or numbers of cigarettes smoking daily (a_10) or “How old were 
you when you start smoking (a_11)? or “How many years of smoking in total(a_12_1).?” 
,then  categorized as former- smokers. 
 
Oslo study I: Those who answered “Yes” to the question “Have you smoked cigarettes daily 
previously” (tidlrok) in Oslo health study were classified as former smokers. In addition, we 
check if a valid value on (tidsidsl) “How long since quitting?!”, if there is a valid value then 
we categorized them as former smokers. 
 
In the Norwegian counties those answering “Yes” to the questions “Have you smoked 
cigarettes daily previously?” were categorized as former-smokers. If answering any value 
(except zero) to the question “How long since you quit smoking?”, and “How many years 
have you smoked daily?” and “how many cigarettes do you or did you smoke daily?”, and not 
a current smoker, then categorized as a former smoker. 
40 years I and II is done similar as the Norwegian Counties. Those answering “Yes” to the 
questions “Have you smoked cigarettes daily previously?” were categorized as former-




smoking?”, and “How many years have you smoked daily?” and “how many cigarettes do you 
or did you smoke daily?”, and not a current smoker, then categorized as a former smoker. 
(Please note the comment from Randi about classification this question in 40 years II.) 
40 years III and IV: any answer more than zero in the question “if you have smoked 
previously, how long since you quit?” then a former smoker. (As answering option is in years, 
we might misclassify those answering zero because they have quit less than 1 year ago.) Also, 
answering any value more than zero to the questions “how many cigarettes do you smoke or 
did you smoke daily”, “how old were you when you started to smoke daily?” or “how many 
years have you smoked daily?”, then classified as former smoker, if not already classified as a 
current smoker. 
 
After we have categorized current and former-smokers, from the remaining group of 
participants, we categorized never-smokers in the following ways: 
 
Never smokers 
CONOR: Answering “No” to the question “Do you smoke daily (a8_0)?”  then never 
smokers. 
In the Norwegian counties study, participants  answering “No” in the questions “Do you 
smoke cigarettes daily?” or Do you smoke cigars daily?” or Do you smoke pipes daily?” and 
if answering  “No” to  the question “Have you smoked cigarettes daily previously?” were 
categorized as never smokers. 
In the 40 years I and II we did the same in the Norwegian counties. Participants  answering 
“No” in the questions “Do you smoke cigarettes daily?” or “Do you smoke cigars daily?” or 
“Do you smoke pipes daily?” and if answering  “No” to  the question “Have you smoked 
cigarettes daily previously?” were categorized as never smokers. 
40 years III: Participants answering “No” to the question “Do you smoke cigarettes daily?” 
Do you smoke cigars daily?” or “Do you smoke pipes daily?”  and not answering the question 
“if you have smoked previously, how long since you quit?”,  then categorized as never 
smoker. 
40 years IV: Participants answering “No” to the questions “Do you smoke cigarettes daily?” 
or “Do you smoke cigars daily?” or “Do you smoke  pipes daily ?” and not answering the 
question “if you have smoked previously, how long since you quit?”, then they are 
categorized as a never smoker. In addition we include the question unique for IV: “Never 
smoked daily?”, then a never smoker. (Brings any records from missing to never, not from 




Oslo: Those answering “No” to the both questions “Do you smoke daily?” and   answering 




Ever-smokers (daily+ former- smokers) 
 
Duration of smoking  
 
The duration of smoking variable was based on two questions. In the CONOR and the Oslo 
health study I, daily and former smokers answered the questions “Numbers of years smoked?” 
In the Norwegian counties study and the 40 years cohort, subjects answering that they were 
ever smokers were asked “How many years all together have you smoked daily?” Duration of 
smoking will be further categorized into three groups (1-29, 30-39 and >40)(Ref: Cigarette 
smoking and risk of colorectal cancer among Norwegian women). Suggestion: Look in EPIC 




Age at smoking initiation  
 
 
The age at smoking initiation variable in CONOR and 40 years III+IV was based on question 
“How old were you when you started smoking”?  
 
In the Norwegian counties study, 40 years I and II cohort and Oslo health study I, this variable 
is constructed. We subtracted total years of smoking from age at enrollment to construct the 





Numbers of cigarettes  
 
The numbers of cigarettes variable was based on question “Numbers of cigarettes smoked 
daily?” in CONOR and Oslo health study I. In  the  Norwegian counties study(I, II and III) 
and 40 years cohort(I,II,III and IV) , ever-smokers were asked “How many cigarettes do you 
smoke/smoked daily?” to extract information on numbers of cigarettes. We will further 
categorized it into three groups (1-9, 10-14 and > 15) (Ref: Gram et al: Cigarette smoking and 
risk of colorectal cancer among Norwegian women). This can be modified during the analysis 





Time since quitting smoking (former smokers only) 
The time since quitting smoking variable was based on question “How long since you have 
quit smoking?” in CONOR, 40 years III and IV. 
Answering option in CONOR and 40 years III and IV was “time in years” continuous 
variable. (rokslutp3 roykslutp4) 
In the Norwegian counties study, Oslo health study I and 40 years I there were four different 
answering options: 
a. Quit since 3 months 
b. Quit since 3 months to 1 year 
c. Quit since 1 to 5 years 
d. Quit for more than 5 years 
 
In 40 years II the question was “If you have smoked previously, how long since you quit” 
with answering options “less than one year” and “more than one year”. (roykslutp2) 
Answers > 60 years is set to missing as outlier (n=4). 
Conclusion: 
 For current smokers “time since quitting smoking” can be handled ok. 
 For former smokers it is a problem for 40 years II because we can only differ between 
<1 year and > 1 year. 
 We decide that former smokers from Norwegian Counties, 40 years I and II and Oslo I 
will be called missing in the continuous variable, but can still be handled as 
categorical variable with four options. 
 
Latency 
We have used information from several variables (see below.). For current smokers the 
information is good. For former smokers, we have information from CONOR and 40 years III 
and IV. The others are set to missing.  
Latency is a constructed variable 
 Latency for current smokers: 
 
a. Years between smoking initiation and cohort enrollment(latency 1) 
or 
b. Years between smoking initiation and censoring/failures(latency 2) 
 
For former-smokers 





In some of the surveys, like in the Norwegian counties study 40 years I+II and 
Oslo health study I, we have “time since quitting” variable which was used for 
constructing latency for former-smokers was available only in four different 
options as: 
1. Less than three months 
2. Three months to 1 year 
3. 1 year to 5 years 
4. 5 years to more 
 
Our main goal was to create a continuous latency variable which was not 




a. Latency  
Latency  1 (Total years from smoking initiation and quitting or cohort enrollment – 
current smokers only) 
b. Latency 2 (Total years between smoking initiation to failure/censoring – current 
smokers only) 
 
c. Latency 3  (Total years between smoking initiation and quitting or cohort 
enrollment- former smokers only)  
“Only for CONOR, 40 years III and IV” 
 
# missing here includes if participants are from other surveys rather than CONOR, 
40 years III and IV”.  
 
d. Latency 4 (Total years between smoking initiation to failure/censuring – former  
smokers only) 




Pack- years of smoking 
This is calculated as number of cigarettes smoked per day, divided by 20 and multiplied by 










The “pipe_smoker_sc” variable yes/no comes from all our surveys.  
 
The amount of pipe smoking ( packs pr week ) will come from 3C I, II, III, 40Y I, II, and Oslo 
I.  Variable name “number_pipetobacco_sc”. 
 
In Oslo 1 they only ask about nr of packs in 3 categories. We have estimated that if answering 
0-0,5 pack will be 0,25 pack, 1-2 packs will be 1,25 and 2 packs will be 2 packs. Then they 
are categorized in the variable “number_pipetobacco_sc”.  
 
Further, if any answer then considered “yes”, if no answer then considered “no”, in the 
“pipe_smoker_sc” variable. 
 







Alcohol Variables  
 
The alcohol variables are from the CONOR and the 40 years study III and IV. The 40 years 




In CONOR and 40 years study III and IV the question was “are you a teetotaler?” and there 
was a “yes/no” answering option.  
We have added the persons who are light/moderate/heavy drinker from the “alcohol 




Our alcohol frequency variable is constructed to become a light, moderate  and heavy (n=42, 
drinker as categorical variable. In general, we have considered a heavy drinker to drink more 




In the CONOR study the variable “drinking pattern” is a 1 to 5 categorical variable: 1. 
Drinking more than once a week 2. Drinking once a week. 3. 2-3 times pr month 4. Once a 
month. 5. Less than once a month. The following categorization has been made: if answering 
1 in CONOR, then categorized as heavy drinker. If answering 2 in Conor, then categorized as 
a moderate drinker. In answering 3,4 or 5 in CONOR, then categorized as a light drinker. 
 
40 years 
There is no information about alcohol consumption in 40 years I and II. In 40 years III and IV 




more pr week, then categorized as a heavy drinker. If drinking 4 times pr month (once a 
week) then categorized as a moderate drinker. If drinking less, then categorized as a light 
drinker. 
 




Alcohol grams pr day  
 
This variable has been constructed from information about drinking frequency and type of 
drink. According to the (ref: www.fhi.no), one glass of wine equals 14,4 grams of pure 
alcohol, one glass of beer equals 11,9 grams of pure alcohol, and one glass of spirits equals 
12,8 grams of pure alcohol. Values larger than 100 grams pr day has been considered 
extreme, and have been set to missing (n=12). 
 
CONOR 
In CONOR the question was “how many glasses of wine / beer / spirits do you drink in a two 
weeks period?” The calculated amount of grams was divided on 14, to get the alcohol 
consumption per day. 
 
40 years 
In 40 years III and IV the question was “how many glasses of wine / beer / spirits do you 




Height and weight were recorded at the health station for all participants, and body mass 
index (BMI) was calculated by standard formula (ref). Observations with extreme values for 
height and weight were set to missing as follows: height <100 or >250 cm, weight <35 or 
>250 kg, BMI <15 or >60 kg/m2.(Ref: T Stocks Me-Can Cohort Profile 2009). 
 






In the analysis we will collapse category 1 and 2 due to low number in category 1 (1.17%) 















Women were categorized as pre-, peri- or postmenopausal. Only 10 per cent of our cohort was 
equal to, or older than 48 years old at inclusion, therefore most in our cohort was 
premenopausal at inclusion.  
 
Questions about menopause were present in CONOR and 40 years III and IV as a continuous 
variable “age at menopause”. In the County Study and in 40 years I and II, this was a question 
with 6 options: “  
1=Ja, menopause inntrådt 
2=Nei, menopause ikke inntrådt 





Answering 1 and 6 were classified as postmenopausal, 2 and 4 were premenopausal, 3 and 5 
were uncertain and classified as the other missing according to age (see below): 
 
If missing information, women were classified as premenopausal if they were less than 46 
years of age. If they were older than 55 years of age, they were classified as postmenopausal. 
Women who were between 46 and 55 years of age were classified as perimenopausal / 
unknown. (Ref: EPIC).  
 
Oral contraceptive use (woman only) 
 
We made the variable “oral contraceptive use” a binary variable (ever / never). In CONOR it 
was reported in questionnaires as current, former or never user, and the current and former 
category were collapsed into ever user by us. There is no information about OC in the County 
Study. 
In the 40 years study, this information was initially collected through interviews, later from 
questionnaires. Due to inconsistent information from several of these studies, we have only 
used information from 40 year III in our study. This is in accordance with advice from tex. 
Anders. 
 
Post- menopausal hormonal therapy (PMHT) (women only) 
 
Post-menopausal hormonal therapy (PMHT) in CONOR was 5 category options, with 
different answering options for never users, former users, and for users of PHT with or 
without prescriptions. In the 40 years study, the answering options were ever, former, never. 




Menarche (women only) 
 
Age at menarche was categorized as a continuous variable. Information about menarche is in 
CONOR and 40 years III and IV. 
 





Women reporting menarche at age 6 years old or less (n=9), or 22 years old or more (n=31), 
were set to missing. 
 
 
Parity (women only) 
 
Information about parity was provided by the Statistics Norway, and is the reported number of 




Age at first childbirth (women only) 
 
Variable created from information provided by the SSB, which provided the year for the 
persons first child, and birth year. 





Smoking exposure before first childbirth (woman only) 
 
Year at first childbirth was given by the SSB. 
Age at smoking initiation is a continuous variable in CONOR and 40 years III and IV. 
 
The age at smoking initiation variable in CONOR and 40 years III+IV was based on question 
“How old were you when you started smoking”?  
 
In the Norwegian counties study, 4o years I and II cohort and Oslo health study I, this variable 
is constructed. We subtracted total years of smoking from age at enrollment to construct the 
age at smoking initiation. This variable was available for both daily and former smokers. 
 
We therefore have good information about smoking exposure before first childbirth, for both 
former and current smokers.  
 
Formulas: 
1. Year of survey assessment – total years of smoking = year of smoking initiation  
  Year of smoking initiation – year of birth = age at smoking initiation 
 
2. Age at enrollment - total years of smoking = age at smoking initiation 
 
 
Total: Age at smoking intiation 
 
 
Year first childbirth – year smoking initiation = years of smoking before first childbirth 
 
Excluded: 





- Smokers initiating after first childbirth 
- No parity 
 
 
In the variable exposure_before_first_childbirth are those with negative number (ie those 





The physical activity variable was created as a 1 to 4 categorical variable, with the variable 
description from CONOR as a reference: 1. Reading, watch TV, other sedentary activity, etc. 
2. Walking, bicycling, etc. 3. Light sports, heavy gardening > 4 hours pr week. 4. Hard 
exercise, competitive sports regularly. In all the included studies except 40 years III, there 
were a 1 to 4 categorical variable.  
 
In the 40 years III, there were two questions for physical activity: “how much light activity do 
you do pr week?”, and “how much heavy activity do you do pr week”, with a 1 to 4 answering 
option for both questions.  
 
If answering 1 or 2 to I aktiv then 1 
3 or 4 to Iaktiv then 2 
1 or 2 to h_aktiv then 3 





Group 1: Light physical 
Group 2: Mild physical activity 
Group 3: Moderate physical activity 





We have information about education level from SSB, and the 1970, 1980 and 1990 census. 
By consensus, we decide to use the highest level of education from the 1980 or 1990 census. 
If the information is missing, then we use the 1970 census. If no information from any census, 
then real missing. 
 
Educational level was given in 1-8 categorical variables from SSB. Value 9 is not answered or 
unknown level of education:  
 
1. 7 years primary school 
2. 9-10 years primary/secondary school 
3. Technical school, middle school, vocational school, 1-2 years senior school 
5. University or university college level 1     
6. University or university college level 2   




8. University researcher level   
 
9. Not answered or unknown level of education 
 
These were merged into four levels of education as follows:  
 
1:  1 and 2 low education level 
2: 3 and 4 low/medium education level 
3: 5 and 6 medium/high education level 
4: 7 and 8 high education level 
 





As for education, information provided by SSB from the 1970, 1980, 1990. Information about 
income was categorized in different ways in the different census, which makes it difficult to 
compare the different time periods. 
 
Income was categorized as follows: Distribution of all incomes at one census was categorized 
in quartiles. The first quartile was given value 1, the second quartile was given value 2, the 
third quartile was given 3, and the fourth quartile was given 4. This was done for all three 
census independently. 
 
The highest quartile registered at either census counted for that individual. The income files 





To create four groups for socioeconomic status (SES), income and education categories were 
added. The sum classified the individuals as follows:  
 
A) 2 score= SES group 1 
B) 3 and 4 score = SES group 2 
C) 5 and 6 score= SES group 3 
D) 7 and 8 score= SES group 4 
 
Comment: we suggest creating 3 SES groups instead of 4. The reason for this is that the 
groups 2 and 3 will be very homogenous, if we create 4 categories.  
 
If we create 3 categories, we will have a low, middle and high SES category, which is a 
common way of classifying social groups. It probably gives a more correct picture of the data, 
as the most important issue about SES will be to differ between low and high SES. We 





















Table: Prospective studies published in the period 2002-2013 examining the association between smoking and risk of colorectal cancer 
Reference, 
location,  
name of study 






Relative risks (95%CI or p value) Adjustment factors/ 
comments 
     Colon cancer Rectal cancer Colorectal cancer  









trial of mammography 
screening. 89835 
women aged 40-59 
years. Follow-up 1982-
1993. Incident 
colorectal cancer or 
death was ascertained 
by computerized record 
linkage to the National 
Mortality Database and 
















































































































 Adjusted for age (in 5- 
year age groups), BMI 
(quartiles), educational 
level, vigorous physical 
activity, hormone 
replacement therapy, 
menopausal status and 
alcohol intake 










frequency matched for 
age and gender. Using 


















Adjusted for age, sex, 
center, coffee and 
alcohol consumption and 
body mass index. 
Reference, 
location,  
name of study 






Relative risks (95%CI or p value) Adjustment factors/ 
comments 
     Colon cancer Rectal cancer Colorectal cancer  
Tiemersma et al. 
(2002), 
(contd) 
Monitoring Project on 
Cardiovascular Disease 




persons aged 20-59 
years. Follow-up 1987-
1998. Incident cancer 
was obtained by record 
linkage with the 
Netherlands Cancer 
Registry and with the 



























































































Adjusted for age, sex, 
center, coffee and 
alcohol consumption and 
body mass index. 







was mailed in January 
1986 to randomly 
selected women aged 
55-69 years, 41836 
(42,7%) responded. 





















Adjusted for age, BMI, 
waist-hip ratio, physical 
activity level, hormone 
replacement therapy, 
alcohol consumption, 
intake of methionine, 













Relative risks (95%CI or p value) Adjustment factors/ 
comments 
     Colon cancer Rectal cancer Colorectal cancer  





































































































sucrose, red meat, 















Relative risks (95%CI or p value) Adjustment factors/ 
comments 
     Colon cancer Rectal cancer Colorectal cancer  
Limburg et al. 
(2003); 
(cont) 



































































Adjusted for age, BMI, 
waist-hip ratio, physical 
activity level, hormone 
replacement therapy, 
alcohol consumption, 
intake of methionine, 
total calories, fat, 
sucrose, red meat, 













No of cases Relative risks (95%CI or p value) Adjustment 
factors/comments 
 
    C R CR
C 
Colon cancer Rectal cancer Colorectal cancer  
Otani et al. 
(2003), 










Cohort I started 1990 
in 5 areas in 5 
prefectures (Iwate, 
Akita, Nagano, 
Okinawa, Tokyo) and 
covered all residents 
aged 40-59. Cohort II 
started 1993 in 6 
areas in 6 prefectures 
(Ibaraki, Niigata, 
Kochi, Nagasaki, 
Okinawa, Osaka) and 
covered all residents 
aged 40-69. 57591 
men and 59103 
women. Active 
follow-up 1990-1999, 
1993- 1999 using 
data of Ministry of 
Health, Labor and 
Welfare for deaths 
and the JPHC cancer 










































































Adjusted for age (5 
year 
groups), family 
history of colorectal 
cancer, BMI, alcohol 
consumption, 
physical 
exercise and 9 Public 













No of cases Relative risks (95%CI or p value) Adjustment 
factors/comments 
 
    C R CR
C 
Colon cancer Rectal cancer Colorectal cancer  
Shimizu et al. 
(2003), 
Japan 
Cohort study with 
31152 residents in 
Takayama, Japan 
who were 35 years 
old or older. Follow 



























































 Adjusted for age, 
height, BMI, alcohol 
intake and years of 
education. 








study in a 
population based 
screening program 







































































No of cases Relative risks (95%CI or p value) Adjustment 
factors/comments 
 
      Colon cancer Rectal cancer Colorectal cancer  









were enrolled from 
45 study areas 
throughout Japan, 
total 59879 eligible 
subjects from 24 
study areas with 
cancer registries 
Follow-up 1988-











































































































































































 Adjusted for age, 
area, education, 




time, sedentary work 
and consumption of 
green leafy 












No of cases Relative risks (95%CI or p value) Adjustment 
factors/comments 
 
      Colon cancer Rectal cancer Colorectal cancer  
Wakai et al. (2003); 
(cont) 

































 Adjusted for age, 
area, education, 




time, sedentary work 
and consumption of 
green leafy 
vegetables and beef. 
 
Colangelo et al. 
(2004), USA, 
The Chicago Heart 
Association 




disease. The CHA 
cohort was screened 
between 1967 and 
1973. 39522 men 
and women from 84 
cooperating 
companies and 




men and 17004 
women remained 
for analyses. Active 
follow-up until 
1979, after 1979 
follow-up until 

























































Adjusted for age, 
race, categories of 
education, body mass 












No of cases Relative risks (95%CI or p value) Adjustment 
factors/comments 
 
      Colon cancer Rectal cancer Colorectal cancer  
Jee et al. (2004), 




from 30 to 95 years 
who received health 










the final sample. 
For information on 
cancer mortality a 
Computerized 
search for death 
certificate data from 
the National 
Statistical Office in 
Korea was 
performed. Active 





















  Adjusted for age. 







who were recruited 
in the UK between 




flagged at the UK 
National health 













  1.0 
1.80 (1.13-2.85) 
1.70 (0.92-3.15) 











No of cases Relative risks (95%CI or p value) Adjustment 
factors/comments 
 
       Colon cancer Rectal cancer Colorectal cancer  





and death. A total 
of 10998 
participants were 
included in the 
analysis. Follow up 
1980-1999 
        Adjusted for age, sex, 
and alcohol. 
Doll et al. (2005) 
United Kingdom 
34439 male British 
doctors, who 
reported their 































































indirectly for age and 
study year 
 
Yun et al. (2005), 





men, 30 years old 
or older who were 




had a medical 
evaluation in 1996. 
Follow-up through 
2000. Incident 
cancer cases were 
identified from the 
Korean Central 















































































 Adjusted for age, 
place of residence, 
BMI, alcohol 
















No of cases Relative risks (95%CI or p value) Adjustment 
factors/comments 
 
       Colon cancer Rectal cancer Colorectal cancer  
Yun et al. (2005); 
(cont) 
 
(KCCR) and six 
regional cancer 
registries (RCRs). 
 Former smokers 


























 Adjusted for age, 
place of residence, 
BMI, alcohol 





vegetables and meats. 




Cohort Study on 
Diet and Cancer 
A total of 58279 
men and 62573 
women between the 
ages of 55 and 69 







cancer cases are 
identified through 
annual record 
linkage to the 
Netherlands Cancer 






The vital status of a 
sub cohort of 3,500 



































































Adjusted for age 
(years), sex, family 
history of colorectal 











No of cases Relative risks (95%CI or p value) Adjustment 
factors/comments 
 
     Colon cancer Rectal cancer Colorectal cancer  
Lüchtenborg et al. 
(2005); (cont) 
 
 was biannually 
examined. Follow 
up 1989-1994. 


















































Adjusted for age 
(years), sex, family 
history of colorectal 
cancer, and BMI. 








with 14103 cohort 
members aged 65 
years or more and 


































































Adjusted for age at 
baseline, gender 
precancerous lesion 
of CRC, medication 
history of NSAID & 
antibiotics, alcohol 











No of cases Relative risks (95%CI or p value) Adjustment 
factors/comments 
 
    CRC Colon cancer Rectal cancer Colorectal cancer  




Follow up for a 
mean of 8.7 person 
years. 
 Smoking duration 
≤ 45 yrs 




≥ age 20 




















Adjusted for age at 
baseline, gender 
precancerous lesion 
of CRC, medication 
history of NSAID & 
antibiotics, alcohol 
drinking and BMI. 
Akhter et al. 
(2007), Japan 
Prospective cohort 
study in 14 
municipalities of 
Miyagi Prefecture 
in rural northern 
Japan. 47605 
Participants aged 
40-64 years (22836 















limited to 21,695 






























































Adjusted for age in 
years, family history 
of colorectal cancer; 
education level, BMI, 
walking time, alcohol 
drinking and current 
drinkers, 
consumption 
frequencies of meat, 
green-yellow 











No of cases Relative risks (95%CI or p value) Adjustment 
factors/comments 
 
    CRC Colon cancer Rectal cancer Colorectal cancer  
Akhter et al. 
(2007);  (cont) 
 
prevalence of 
smoking in women. 
 Smoking duration 
≤ 45 yrs 




≥ age 20 




















Adjusted for age in 
years, family history 
of colorectal cancer; 
education level, BMI, 
walking time, alcohol 
drinking and current 
drinkers, 
consumption 
frequencies of meat, 
green-yellow 
vegetables and fruits 








Collaboration of 33 
cohort studies in the 
region. 539201 
participants (35% 
female, 65% male). 
Studies were 
included if they had 
continued follow-
up for at least 5000 
person-years and 
had recorded vital 
status at the end of 
follow-up. Data on 
cigarette smoking 





























Adjusted for diabetes, 











No of cases Relative risks (95%CI or p value) Adjustment 
factors/comments 
 
     Colon cancer Rectal cancer Colorectal cancer  




The WHI includes 
an observational 






the clinical files and 























































































































 Adjusted for age 
ethnicity, study arm, 
family history of 
colorectal cancer, 





drug use, alcohol, 
hormone therapy use, 
colonoscopy, history 
of diabetes, total 
dietary calcium, total 
dietary fibre, percent 
energy from fat, 
hemoglobin, waist 
circumference, red 
meat intake, and 
















No of cases Relative risks (95%CI or p value) Adjustment 
factors/comments 
 
    C R CR
C 
Colon cancer Rectal cancer Colorectal cancer  















































































































 Adjusted for age, 
gender, dialect group, 
year of recruitment, 
level of education, 
BMI, history of 
diabetes, family 




Batty et al. (2008), 






participated in a 
medical 
examination in the 
1960s (response 




using procedures of 
the National Health 
Service Central 











Effect per 10 
cigarettes/d 





Effect per 10 
cigarettes/d 





































 Adjusted for age, 
employment grade, 
physical activity, 
BMI, marital status, 
systolic and diastolic 
blood pressure, 
cholesterol forced 
expiratory volume in 
1s, height, impaired 
glucose tolerance, 











No of cases Relative risks (95%CI or p value) Adjustment 
factors/comments 
 
      Colon cancer Rectal cancer Colorectal cancer  
Kenfield et al. 
(2008), USA, 
The Nurses Health 
Study 
Established 1976, 
121700 female US 
registered nurses 
aged 30 up to 55 
years, residing in 11 
states. Baseline 
information 
obtained by mailed 
questionnaire. 
Deaths were usually 
reported by families 
and deaths among 
nonrespondents 
were identified by 
searching the 
National Death 























































































Adjusted for age 
(months), follow-up 




BMI, change in 
weight from age 18 
years to baseline 
(1980), alcohol 
intake, physical 




estrogen therapy use 
and menopausal 
status, parental 
history of myocardial 
infarction at age 65 
years or younger 
and age at starting 
smoking, servings of 
beef, pork, lamb or 
processed meat, total 
calcium and folate 
intake, and duration 



















No of cases Relative risks (95%CI or p value) Adjustment 
factors/comments 
 
    C R CRC Colon cancer Rectal cancer Colorectal cancer  






68160 women aged 
30- 69 years who 
completed a 
questionnaire in 
1996 or 1998. 
Follow-up by 


























































































































































































 Adjusted for age, 
menopausal status, hormonal 
contraceptive and 
postmenopausal hormonal 
therapy use, BMI and 












No of cases Relative risks (95%CI or p value) Adjustment 
factors/comments 
 
    C R CRC Colon cancer Rectal cancer Colorectal cancer  
Gram et al. 
(2009); 
(cont) 




































  Adjusted for age, 
menopausal status, hormonal 
contraceptive and 
postmenopausal hormonal 
therapy use, BMI and 
alcohol consumption, all at 
enrolment. 
Hannan et al. 
(2009), U.S. 
Participants were 
drawn from the 
Cancer Prevention 
Study II Nutrition 
Cohort, a sub 
cohort of the CPS II 
mortality cohort, 
including residents 
in 21 states with 
population based 
state cancer 
registries and 50 to 
74 years of age in 
1992. Participants 




sent in 1997, 1999, 
2001, 2003, and 
2005, with response 




























Age at cessation 
Before age 40 
40-49 yrs of age 
50-59 yrs of age 




≥ 31 yrs ago 
21-30 yrs ago 
11-20 yrs ago 










































Adjusted for age , BMI, 
education, family history of 
colorectal cancer, physical 




consumption, red and 
processed meat 












No of cases Relative risks (95%CI or p value) Adjustment 
factors/comments 
 
    CRC Colon cancer Rectal cancer Colorectal cancer  
Hannan et al. 
(2009); 
(cont) 
participants at least 
89%. The follow up 
period ended on 
June 30, 2005. 
51365 men and 
73386 women were 
included in the 
analysis. 
Incident cases of 
colorectal cancer 
were identified by 
ICD-9 codes 153-
























Adjusted for age , BMI, 
education, family history of 
colorectal cancer, physical 




consumption, red and 
processed meat 





participants in a 
population-based 
cohort study (the 
Iowa Women's 
Health Study) 











Adjusted for age, BMI, 
waist-hip, physical activity, 
alcohol, exogenous estrogen, 
daily intake of total calories, 
fat, sucrose, red meat, 





































2741 CRC  




















































Adjusted for weight, height, 
physical activity, education, 
dietary intake of energy 
from fat, energy from non-
fat, fiber, fruit, vegetables, 
red meat, processed meat, 











No of cases Relative risks (95%CI or p value) Adjustment 
factors/comments 
 




 cases.  Distal colon 
cancer 
















  Adjusted for weight, height, 
physical activity, education, 
dietary intake of energy 
from fat, energy from non-
fat, fiber, fruit, vegetables, 
red meat, processed meat, 
alcohol, and fish 
Parajuli et al. 
(2013), 
Norway 
602, 242 men and 


































































































  Adjusted for age, physical 












No of cases Relative risks (95%CI or p value) Adjustment 
factors/comments 
    C R CRC 
 
Colon cancer Rectal cancer Colorectal cancer  












  Adjusted for age, physical 





Distal colon   
cancer  1.0 
Never smokers 295 1.15(0.94-1.41) 
Former smokers 132 1.12(0.93-1.34) 
Current smokers 227 1.13(0.96-1.32) 
Ever smokers 359  
Men   







Current smokers 874 1.03(0.92-1.15) 
Ever smokers 1,618 1.08(0.97-1.19) 
Proximal colon   













Distal colon   
cancer   
Never smokers 217 1.0 
Former smokers 323 1.24(1.03-1.47) 
Current smokers 326 0.95(0.79-1.13) 
Ever smokers 649 1.08(0.92-1.26) 
 
Source: International Agency on Research on Cancer (IARC) monograph 100 E 2012 for the cohorts until 2009 
